Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW

Thank you in advance for your participation.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:17:36 ON 02 MAY 2006

=> file pctfull
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'PCTFULL' ENTERED AT 07:17:44 ON 02 MAY 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 2 MAY 2006 <20060502/UP>
MOST RECENT UPDATE WEEK: 200617 <200617/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE
http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

=> s 25-hydroxyvitamin D
688145 25
371 HYDROXYVITAMIN
4 HYDROXYVITAMINS
371 HYDROXYVITAMIN
(HYDROXYVITAMIN OR HYDROXYVITAMINS)
1068679 D
L1 130 25-HYDROXYVITAMIN D
(25(W)HYDROXYVITAMIN(W)D)

=> s calcidiol or calcifediol or calderol or dedrogyl or didrogyl or hidroferol
17 CALCIDIOL
99 CALCIFEDIOL
3 CALDEROL

```
             0 DEDROGYL
             0 DIDROGYL
             0 HIDROFEROL
L2         115 CALCIDIOL OR CALCIFEDIOL OR CALDEROL OR DEDROGYL OR DIDROGYL OR
               HIDROFEROL

=> s l2 or l1
L3         239 L2 OR L1

=> s cancer? or tumor? or neoplas?
         77789 CANCER?
         65076 TUMOR?
         22573 NEOPLAS?
L4       96951 CANCER? OR TUMOR? OR NEOPLAS?

=> s l4 and l3
L5         171 L4 AND L3

=> s l3/ab
             0 CALCIDIOL/AB
             1 CALCIFEDIOL/AB
             0 CALDEROL/AB
             0 DEDROGYL/AB
             0 DIDROGYL/AB
             0 HIDROFEROL/AB
         31048 25/AB
            23 HYDROXYVITAMIN/AB
        968384 D/AB
             3 25-HYDROXYVITAMIN D/AB
                 ((25(W)HYDROXYVITAMIN(W)D)/AB)
L6           4 ((CALCIDIOL/AB OR CALCIFEDIOL/AB OR CALDEROL/AB OR DEDROGYL/AB
               OR DIDROGYL/AB OR HIDROFEROL/AB) OR (25-HYDROXYVITAMIN D/AB))

=> s l6 and l4
L7           1 L6 AND L4

=> d ibib

L7     ANSWER 1 OF 1     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        1999049027 PCTFULL  ED 20020515
TITLE (ENGLISH):         METHODS FOR PREVENTION AND TREATMENT OF CANCER
TITLE (FRENCH):          METHODES DE PREVENTION ET DE TRAITEMENT DU
                         CANCER
INVENTOR(S):             SCHWARTZ, Gary, G.;
                         LOKESHWAR, Balakrishna, L.;
                         CHEN, Tai, C.;
                         WHITLATCH, Lyman, W.;
                         KONG, Xiang, Fu;
                         HOLICK, Michael, F.
PATENT ASSIGNEE(S):      CUTANOGEN, INC.;
                         SCHWARTZ, Gary, G.;
                         LOKESHWAR, Balakrishna, L.;
                         CHEN, Tai, C.;
                         WHITLATCH, Lyman, W.;
                         KONG, Xiang, Fu;
                         HOLICK, Michael, F.
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER             KIND     DATE
                         ---------------------------------
                         WO 9949027           A1 19990930
DESIGNATED STATES
```

```
       W:              AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
                       EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
                       KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
                       PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
                       YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
                       MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
                       MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
                       TG
APPLICATION INFO.:     WO 1999-US6491       A  19990325
PRIORITY INFO.:        US 1998-09/047,918      19980325
                       US 1999-60/122,270      19990301
                       US 1999-60/122,268      19990301
                       US 1999-60/123,669      19990309
                       US 1999-60/123,670      19990309


=> d his

     (FILE 'HOME' ENTERED AT 07:17:36 ON 02 MAY 2006)

     FILE 'PCTFULL' ENTERED AT 07:17:44 ON 02 MAY 2006
L1          130 S 25-HYDROXYVITAMIN D
L2          115 S CALCIDIOL OR CALCIFEDIOL OR CALDEROL OR DEDROGYL OR DIDROGYL
L3          239 S L2 OR L1
L4        96951 S CANCER? OR TUMOR? OR NEOPLAS?
L5          171 S L4 AND L3
L6            4 S L3/AB
L7            1 S L6 AND L4

=> s l3/clm
              1 CALCIDIOL/CLM
             19 CALCIFEDIOL/CLM
              0 CALDEROL/CLM
              0 DEDROGYL/CLM
              0 DIDROGYL/CLM
              0 HIDROFEROL/CLM
         406864 25/CLM
             63 HYDROXYVITAMIN/CLM
         331377 D/CLM
             11 25-HYDROXYVITAMIN D/CLM
                  ((25(W)HYDROXYVITAMIN(W)D)/CLM)
L8           30 ((CALCIDIOL/CLM OR CALCIFEDIOL/CLM OR CALDEROL/CLM OR DEDROGYL/C
                LM OR DIDROGYL/CLM OR HIDROFEROL/CLM) OR (25-HYDROXYVITAMIN
                D/CLM))

=> s l8 and l4
L9           17 L8 AND L4

=> s l9 not py>1999
         675200 PY>1999
L10           4 L9 NOT PY>1999

=> d ibib 1-4

L10    ANSWER 1 OF 4     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:       1999049027 PCTFULL  ED 20020515
TITLE (ENGLISH):        METHODS FOR PREVENTION AND TREATMENT OF CANCER
TITLE (FRENCH):         METHODES DE PREVENTION ET DE TRAITEMENT DU
                        CANCER
INVENTOR(S):            SCHWARTZ, Gary, G.;
                        LOKESHWAR, Balakrishna, L.;
                        CHEN, Tai, C.;
                        WHITLATCH, Lyman, W.;
```

KONG, Xiang, Fu;
HOLICK, Michael, F.

PATENT ASSIGNEE(S): CUTANOGEN, INC.;
SCHWARTZ, Gary, G.;
LOKESHWAR, Balakrishna, L.;
CHEN, Tai, C.;
WHITLATCH, Lyman, W.;
KONG, Xiang, Fu;
HOLICK, Michael, F.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9949027	A1	19990930

DESIGNATED STATES
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 1999-US6491	A	19990325
PRIORITY INFO.:	US 1998-09/047,918		19980325
	US 1999-60/122,270		19990301
	US 1999-60/122,268		19990301
	US 1999-60/123,669		19990309
	US 1999-60/123,670		19990309

L10 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998018610 PCTFULL ED 20020514
TITLE (ENGLISH): EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES
TITLE (FRENCH): INCLUSION ET ENCAPSULATION DE PARTICULES A LIBERATION CONTROLEE
INVENTOR(S): VAN LENGERICH, Bernhard, H.
PATENT ASSIGNEE(S): VAN LENGERICH, Bernhard, H.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9818610	A1	19980507

DESIGNATED STATES
W: AU CA JP NO PL US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.:	WO 1997-US18984	A	19971027
PRIORITY INFO.:	US 1996-60/029,038		19961028
	US 1997-60/052,717		19970716

L10 ANSWER 3 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1997013518 PCTFULL ED 20020514
TITLE (ENGLISH): TREATMENT OF PRURITUS WITH VITAMIN D AND ANALOGS THEREOF
TITLE (FRENCH): TRAITEMENT DU PRURIT A L'AIDE DE VITAMINE D ET D'ANALOGUES DE CELLE-CI
INVENTOR(S): STRUBE, Marilyn
PATENT ASSIGNEE(S): STRUBE, Marilyn
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

```
                        NUMBER              KIND     DATE
                        ---------------------------------
                        WO 9713518            A1 19970417
DESIGNATED STATES
       W:               AL AM AU BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR
                        LK LR LS LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT
                        UA UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM
                        AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
                        BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.:      WO 1996-US15016       A  19960918
PRIORITY INFO.:         US 1995-60/005,030       19951010

L10    ANSWER 4 OF 4     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:       1994006435 PCTFULL  ED 20020513
TITLE (ENGLISH):        METHOD OF TREATING PREMENSTRUAL SYNDROME SYMPTOMATOLOGY
                        WITH VITAMIN D OR VITAMIN D AND CALCIUM
TITLE (FRENCH):         PROCEDE DE TRAITEMENT DE LA SYMPTOMATOLOGIE DU SYNDROME
                        PREMENSTRUEL PAR LA VITAMINE D OU LA VITAMINE D ET LE
                        CALCIUM COMBINES
INVENTOR(S):            THYS-JACOBS, Susan
PATENT ASSIGNEE(S):     THYS-JACOBS, Susan
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER              KIND     DATE
                        ---------------------------------
                        WO 9406435            A1 19940331
DESIGNATED STATES
       W:               CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.:      WO 1993-US8653        A  19930914
PRIORITY INFO.:         US 1992-945,319          19920915
                        US 1993-59,682           19930510


=> file his
'HIS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'PCTFULL'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> d his

     (FILE 'HOME' ENTERED AT 07:17:36 ON 02 MAY 2006)

     FILE 'PCTFULL' ENTERED AT 07:17:44 ON 02 MAY 2006
L1           130 S 25-HYDROXYVITAMIN D
L2           115 S CALCIDIOL OR CALCIFEDIOL OR CALDEROL OR DEDROGYL OR DIDROGYL
L3           239 S L2 OR L1
L4         96951 S CANCER? OR TUMOR? OR NEOPLAS?
L5           171 S L4 AND L3
L6             4 S L3/AB
L7             1 S L6 AND L4
L8            30 S L3/CLM
L9            17 S L8 AND L4
L10            4 S L9 NOT PY>1999

=> s l4/clm
          22256 CANCER?/CLM
          15135 TUMOR?/CLM
           3660 NEOPLAS?/CLM
L11       31772 (CANCER?/CLM OR TUMOR?/CLM OR NEOPLAS?/CLM)
```

```
=> s l11 and l8
L12          9 L11 AND L8

=> s l12 not py>1998
        742760 PY>1998
L13          1 L12 NOT PY>1998

=> d ibib

L13    ANSWER 1 OF 1     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        1998018610 PCTFULL  ED 20020514
TITLE (ENGLISH):         EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE
                         PARTICLES
TITLE (FRENCH):          INCLUSION ET ENCAPSULATION DE PARTICULES A LIBERATION
                         CONTROLEE
INVENTOR(S):             VAN LENGERICH, Bernhard, H.
PATENT ASSIGNEE(S):      VAN LENGERICH, Bernhard, H.
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         ---------------------------------
                         WO 9818610            A1 19980507
DESIGNATED STATES
       W:                AU CA JP NO PL US AT BE CH DE DK ES FI FR GB GR IE IT
                         LU MC NL PT SE
APPLICATION INFO.:       WO 1997-US18984       A  19971027
PRIORITY INFO.:          US 1996-60/029,038       19961028
                         US 1997-60/052,717       19970716


=> d kwic

L13    ANSWER 1 OF 1     PCTFULL   COPYRIGHT 2006 Univentio on STN

CLMEN.  .  .  biotin,
       biperiden, bisacodyl, bismuth, botulism antitoxin, bromocriptine
       mesylate,
       bromodiphenhydrarnine hydrochloride, bumetanide, bupivacaine, busulfan
       butabarbital sodium,butalbital, combinations of butalbital, caffeine and
       aspirin
       and codeine, beta-carotene, calcifediol, calcium carbonate,
       calcium citrate,
       calcium salts, candicidin, captopril, carbachol, carbamazepine,
       carbenicillin
       indanyl sodium, carbidopa, carbinoxamine maleate, carboprost
       tromethamine,
       carboxymethylcellulose, carisoprodol, casanthranol, cascara, castor.  .
       .
  .  .  .
       antibiotics, nutritional supplements, enzymes, fonnations
       containing zidovudine, macromolecular polypeptides, aromatic nitro and
       nitroso
       compounds and their metabolites useful as anti-viral and anti
       tumor agents, HIV
       protease inhibitors, antibiotics, viruses, pigments, steroids,
       oligopeptides,
       dipeptides, amino acids, flavor components, fragrance components,
       detergents
       and surface-active components, lipid derivatives of.  .  .
```

=> d kwic l10 3

L10 ANSWER 3 OF 4 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . a variety of conditions
although undesirable side effects can be produced by UV light such as an increased risk of developing skin **cancer** as well as undesirable phototoxic reactions (see for example, Marks, J Dermatol Treat 1:233-234, 1989) Thus it would be desirable to develop new. . .

CLMEN 3 The method according to claim 2 wherein the vitamin D comprises a compound selected from the group consisting of alacalcidol, **calcifediol**, calcitriol, cholecalciferol, dihydrotachysterol and ergocalciferol.

10 The method according to claim 9 wherein the vitamin D comprises a compound selected from the group consisting of alacalcidol, **calcifediol**, calcitriol, cholecalciferol, dihydrotachysterol and ergocalciferol.

16 The method according to claim 15 wherein the vitamin D comprises a compound selected from the group consisting of alacalcidol, **calcifediol**, calcitriol, cholecalciferol, dihydrotachysterol and ergocalciferol.

=> file dissab

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.14	14.35

FILE 'DISSABS' ENTERED AT 07:22:40 ON 02 MAY 2006

FILE COVERS 1861 TO 28 APR 2006 (20060428/ED)

=> s 25-hydroxyvitamin D
43064 25
107 HYDROXYVITAMIN
107815 D
L14 78 25-HYDROXYVITAMIN D
(25(W)HYDROXYVITAMIN(W)D)

=> s calcidiol or calcifediol or calderol or dedrogyl or didrogyl or hidroferol
3 CALCIDIOL
0 CALCIFEDIOL
0 CALDEROL
0 DEDROGYL
0 DIDROGYL
0 HIDROFEROL
L15 3 CALCIDIOL OR CALCIFEDIOL OR CALDEROL OR DEDROGYL OR DIDROGYL OR HIDROFEROL

```
=> s l14 or l15
L16         81 L14 OR L15

=> s cancer? or tumor? or neoplas?
         15842 CANCER?
         13357 TUMOR?
          2399 NEOPLAS?
L17      25728 CANCER? OR TUMOR? OR NEOPLAS?

=> s l16 and l17
L18         11 L16 AND L17

=> s l18 not py>2000
        277812 PY>2000
L19          7 L18 NOT PY>2000

=> s l18 not py>1999
        336292 PY>1999
L20          7 L18 NOT PY>1999

=> d ibib 1-7

L20  ANSWER 1 OF 7  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   2001:22784  DISSABS   Order Number: AAIC802686 (not
                    available for sale by UMI)
TITLE:              Metabolic bone disease in children with cancer
AUTHOR:             Arikoski, Pekka Matti [xx]
CORPORATE SOURCE:   Kuopion Yliopisto (Finland) (5754)
SOURCE:             Dissertation Abstracts International, (1999) Vol. 61, No.
                    3C, p. 769. Order No.: AAIC802686 (not available for sale
                    by UMI). Kuopio University Publications, University of
                    Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland. 114 pages

                    ISBN: 951-781-771-1.
DOCUMENT TYPE:      Dissertation
FILE SEGMENT:       DAI
LANGUAGE:           English

L20  ANSWER 2 OF 7  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   1998:2848  DISSABS   Order Number: AAR9803618
TITLE:              VITAMIN D AND BREAST CANCER RISK
AUTHOR:             JANOWSKY, ESTHER CELIA [PH.D.]; HULKA, BARBARA S. [adviser]
CORPORATE SOURCE:   THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (0153)
SOURCE:             Dissertation Abstracts International, (1997) Vol. 58, No.
                    8B, p. 4172. Order No.: AAR9803618. 111 pages.
DOCUMENT TYPE:      Dissertation
FILE SEGMENT:       DAI
LANGUAGE:           English

L20  ANSWER 3 OF 7  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   97:46594  DISSABS   Order Number: AAR9719037
TITLE:              VITAMIN D STATUS AND RISK OF LARGE BOWEL CANCER
AUTHOR:             TANGREA, JOSEPH ANTHONY [PH.D.]
CORPORATE SOURCE:   THE JOHNS HOPKINS UNIVERSITY (0098)
SOURCE:             Dissertation Abstracts International, (1996) Vol. 58, No.
                    1B, p. 160. Order No.: AAR9719037. 342 pages.
DOCUMENT TYPE:      Dissertation
FILE SEGMENT:       DAI
LANGUAGE:           English
ENTRY DATE:         Entered STN: 19970604
```

Last Updated on STN: 19970604

L20 ANSWER 4 OF 7 DISSABS COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved on STN
ACCESSION NUMBER: 94:8342 DISSABS Order Number: AAR9330164
TITLE: MOLECULAR STUDIES OF 1,25-DIHYDROXYVITAMIN D(3)-RESPONSIVE PROTEINS IN HUMAN PROMYELOCYTIC HL-60 CELLS (VITAMIN D(3) RESPONSIVE PROTEINS, DIHYDROXY VITAMINS)
AUTHOR: CHEN, KAI-SHUN [PH.D.]; DELUCA, HECTOR F. [advisor]
CORPORATE SOURCE: THE UNIVERSITY OF WISCONSIN - MADISON (0262)
SOURCE: Dissertation Abstracts International, (1993) Vol. 54, No. 9B, p. 4645. Order No.: AAR9330164. 140 pages.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: English
ENTRY DATE: Entered STN: 19940218
Last Updated on STN: 19940218

L20 ANSWER 5 OF 7 DISSABS COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved on STN
ACCESSION NUMBER: 93:46805 DISSABS Order Number: AAR9324012
TITLE: VITAMIN D AND PROSTATE **CANCER**: A PREDIAGNOSTIC STUDY WITH STORED SERA
AUTHOR: CORDER, ELIZABETH HEDLUND [PH.D.]; GUESS, HARRY A. [advisor]
CORPORATE SOURCE: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (0153)
SOURCE: Dissertation Abstracts International, (1993) Vol. 54, No. 4B, p. 1917. Order No.: AAR9324012. 90 pages.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: English
ENTRY DATE: Entered STN: 19930920
Last Updated on STN: 19930920

L20 ANSWER 6 OF 7 DISSABS COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved on STN
ACCESSION NUMBER: 91:17277 DISSABS Order Number: AAR9135434
TITLE: REGULATION OF FRUCTOSE 1,6-BISPHOSPHATASE EXPRESSION DURING MONOCYTIC DIFFERENTIATION (FRUCTOSE BISPHOSHATASE EXPRESSION)
AUTHOR: SOLOMON, DAVID HORN [PH.D.]
CORPORATE SOURCE: CORNELL UNIVERSITY MEDICAL COLLEGE (0967)
SOURCE: Dissertation Abstracts International, (1991) Vol. 52, No. 7B, p. 3443. Order No.: AAR9135434. 149 pages.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: English
ENTRY DATE: Entered STN: 19921118
Last Updated on STN: 19921118

L20 ANSWER 7 OF 7 DISSABS COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved on STN
ACCESSION NUMBER: 87:24616 DISSABS Order Number: AAR8801539
TITLE: CHAPTER I: A-1,4-ASYMMETRIC INDUCTION BY DESILYLATION OF TRIMETHYLSILYL ALCOHOLS. B-CARBON-CARBON BOND FORMATION IN WATER AND APPLICATION TO THE SYNTHESIS OF AN INTERMEDIATE FOR BOROMYCIN. CHAPTER II: CONSTRUCTION OF THE SIDE CHAIN OF 25-HYDROXY-VITAMIN-D2 AND ANALOGUES BY SOLVOLYSIS OF CYCLOPROPYL CARBINOLS
AUTHOR: GUAZZARONI, MARIA E. [PH.D.]
CORPORATE SOURCE: NEW YORK UNIVERSITY (0146)
SOURCE: Dissertation Abstracts International, (1987) Vol. 48, No. 11B, p. 3287. Order No.: AAR8801539. 381 pages.

DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: English
ENTRY DATE: Entered STN: 19921118
Last Updated on STN: 19921118

=> d kwic 5

L20 ANSWER 5 OF 7 DISSABS COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved on STN

TI VITAMIN D AND PROSTATE **CANCER**: A PREDIAGNOSTIC STUDY WITH STORED SERA

AB . . . of two epidemiologic studies. The first is a descriptive study that considers whether increases in the reported frequency of prostate **cancer** may be the result of more complete case ascertainment in recent years. The second is a molecular epidemiologic study that evaluates the risk of prostate **cancer** in relation to serum levels of vitamin D metabolites.

When autopsy cases are included, the incidence of prostate **cancer** did not increase in Rochester, Minnesota, from 1935 until introduction of prostate specific antigen (PSA) assay in 1988. Incidence doubled. . . Kaiser Permanente Medical Care Plan of Northern California and stored for future use. One hundred black and 100 white prostate **cancer** cases diagnosed before December 31, 1987 were selected from men with stored sera. Each case was matched to one control. . . 1,25-dihydroxyvitamin D (1,25-D) was 1.81 pg/ml lower in cases than in matched controls ($p = 0.002$). The risk of prostate **cancer** decreased with higher levels of 1,25-D, especially in men with low levels of **25-hydroxyvitamin D** (25-D). However, mean 25-D was not significantly different in cases compared to matched controls. The association of lower 1,25-D with prostate **cancer** was found in men above the median age of 57 years at serum storage but not in younger men and. . . men. In men at least 57 years of age, 1,25-D was an important predictor of risk for palpable and anaplastic **tumors** but not for incidentally discovered or well-differentiated **tumors**. We conclude that men with higher serum levels of 1,25-D have reduced risk of prostate **cancer**.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW

Thank you in advance for your participation.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:57:47 ON 02 MAY 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 06:58:14 ON 02 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2006 HIGHEST RN 882489-85-2
DICTIONARY FILE UPDATES: 1 MAY 2006 HIGHEST RN 882489-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> E "25-HYDROXYVITAMIN D"/CN 25
E1            1     25-HYDROXYSITOSTEROL/CN
E2            1     25-HYDROXYTACHYSTEROL3/CN
E3            3 --> 25-HYDROXYVITAMIN D/CN
E4            1     25-HYDROXYVITAMIN D 1-HYDROXYLASE/CN
E5            1     25-HYDROXYVITAMIN D 1A-HYDROXYLASE (MOUSE STRAIN 129/SVJ GENE
CYP27B1)/CN
E6            1     25-HYDROXYVITAMIN D 24-HYDROXYLASE/CN
E7            1     25-HYDROXYVITAMIN D-1A-HYDROXYLASE/CN
E8            1     25-HYDROXYVITAMIN D-1A-HYDROXYLASE (HUMAN KERATINOCYTE GENE
CYP1)/CN
E9            1     25-HYDROXYVITAMIN D2/CN
E10           1     25-HYDROXYVITAMIN D2 25-GLUCURONIDE/CN
E11           1     25-HYDROXYVITAMIN D2 25-GLUCURONIDE METHYL ESTER/CN
E12           1     25-HYDROXYVITAMIN D2 3-ACETATE/CN
E13           1     25-HYDROXYVITAMIN D3/CN
E14           1     25-HYDROXYVITAMIN D3 1-HYDROXYLASE/CN
E15           1     25-HYDROXYVITAMIN D3 1A-HYDROXYLASE/CN
E16           1     25-HYDROXYVITAMIN D3 1A-HYDROXYLASE (HUMAN KIDNEY)/CN
E17           1     25-HYDROXYVITAMIN D3 1A-HYDROXYLASE (HUMAN)/CN
E18           1     25-HYDROXYVITAMIN D3 1A-HYDROXYLASE (MOUSE KIDNEY)/CN
E19           1     25-HYDROXYVITAMIN D3 1A-HYDROXYLASE (SWINE CLONE 1AH54)/CN
E20           1     25-HYDROXYVITAMIN D3 23-HYDROXYLASE/CN
E21           1     25-HYDROXYVITAMIN D3 24-HYDROXYLASE/CN
E22           1     25-HYDROXYVITAMIN D3 24-HYDROXYLASE (RAT CLONE PCC24-8)/CN
E23           1     25-HYDROXYVITAMIN D3 24R-HYDROXYLASE/CN
E24           1     25-HYDROXYVITAMIN D3 25-GLUCURONIDE/CN
E25           1     25-HYDROXYVITAMIN D3 25-SULFATE/CN

=> S E3
L1            3 "25-HYDROXYVITAMIN D"/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 3  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   64719-49-9  REGISTRY
CN   Vitamin D, 25-hydroxy- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   25-Hydroxyvitamin D
MF   Unspecified
CI   MAN
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
       CIN, EMBASE, IPA, MEDLINE, PROMT, TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Conference; Journal; Patent
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       OCCU (Occurrence); PREP (Preparation); PROC (Process); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  BIOL (Biological
       study)
```

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
             862 REFERENCES IN FILE CA (1907 TO DATE)
               2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             864 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.54       7.75

FILE 'CAPLUS' ENTERED AT 06:59:16 ON 02 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 May 2006  VOL 144 ISS 19
FILE LAST UPDATED: 1 May 2006  (20060501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1
L2        4159 L1

=> s cancer? or tumor? or neoplas?
        291257 CANCER?
        426036 TUMOR?
        447058 NEOPLAS?
L3      705552 CANCER? OR TUMOR? OR NEOPLAS?

=> s l2 (l) l3\
         10926 L3\
                 ('L3')
L4           1 L2 (L) L3\

=> s l2 (l) l3
L5          78 L2 (L) L3

=> s l5 not py>1998
       7447350 PY>1998
L6          22 L5 NOT PY>1998

=> d ibib 1-10

L6   ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1998:452435  CAPLUS
DOCUMENT NUMBER:          129:131487
TITLE:                    Markers of bone turnover in patients with
```

differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy
AUTHOR(S): Toivonen, Jukka; Tahtela, Riitta; Laitinen, Kalevi; Risteli, Juha; Valimaki, Matti J.
CORPORATE SOURCE: Department of Medicine, Helsinki University Central Hospital, Helsinki, FIN-00290, Finland
SOURCE: European Journal of Endocrinology (1998), 138(6), 667-673
CODEN: EJOEEP; ISSN: 0804-4643
PUBLISHER: BioScientifica
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:319281 CAPLUS
DOCUMENT NUMBER: 129:66214
TITLE: Renal tubular reabsorption of phosphate is positively related to the extent of bone metastatic load in patients with prostate cancer
AUTHOR(S): Buchs, Nicolas; Bonjour, Jean-Philippe; Rizzoli, Rene
CORPORATE SOURCE: Division of Bone Diseases, World Health Organization Collaborating Center for Osteoporosis and Bone Diseases, Department of Internal Medicine, University Hospital, Geneva, 1211/14, Switz.
SOURCE: Journal of Clinical Endocrinology and Metabolism (1998), 83(5), 1535-1541
CODEN: JCEMAZ; ISSN: 0021-972X
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:511176 CAPLUS
DOCUMENT NUMBER: 127:185673
TITLE: Effect of clodronate on calcidiol serum levels in women with breast cancer
AUTHOR(S): Martinez, M. E.; Pastrana, P.; Sanchez-Cabezudo, M. J.; Jariego, C.; Del Campo, M. T.
CORPORATE SOURCE: Biochemistry Division, La Paz Hospital, Madrid, 28046, Spain
SOURCE: Calcified Tissue International (1997), 61(2), 148-150
CODEN: CTINDZ; ISSN: 0171-967X
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:688150 CAPLUS
DOCUMENT NUMBER: 123:132206
TITLE: 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1α,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis
AUTHOR(S): Wali, Ramesh K.; Bissonnette, Marc; Khare, Sharad; Hart, John; Sitrin, Michael D.; Brasitus, Thomas A.
CORPORATE SOURCE: Dep. of Medicine and Pathology, Univ. of Chicago, Chicago, IL, 60637, USA

SOURCE: Cancer Research (1995), 55(14), 3050-4
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:326434 CAPLUS
DOCUMENT NUMBER: 122:96002
TITLE: Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3
AUTHOR(S): Skowronski, Roman J.; Peehl, Donna M.; Feldman, David
CORPORATE SOURCE: Dep. Med. and Urology (D.M.P.), Stanford Univ. Sch. Med., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1995), 136(1), 20-6
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:554464 CAPLUS
DOCUMENT NUMBER: 121:154464
TITLE: Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line
AUTHOR(S): Mawer, E. Barbara; Hayes, Michael E.; Heys, Sara E.; Davies, Michael; White, Anne; Stewart, M. Felicity; Smith, George N.
CORPORATE SOURCE: Bone Disease Res. Cent., Manchester Univ., Manchester, UK
SOURCE: Journal of Clinical Endocrinology and Metabolism (1994), 79(2), 554-60
CODEN: JCEMAZ; ISSN: 0021-972X
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:183910 CAPLUS
DOCUMENT NUMBER: 120:183910
TITLE: Role of the 75 kD- and 55 kD-receptors in tumor necrosis factor mediated cytotoxicity and its regulation by dexamethasone and by 1,25-dihydroxyvitamin D3 in U937 cells
AUTHOR(S): Chambaut-Guerin, Anne Marie; Guerrier, Maguy; Thomopoulos, Pierre
CORPORATE SOURCE: INSERM U282, Hop. Henri Mondor, Creteil, 94010, Fr.
SOURCE: European Cytokine Network (1993), 4(4), 285-92
CODEN: ECYNEJ; ISSN: 1148-5493
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:72532 CAPLUS
DOCUMENT NUMBER: 120:72532
TITLE: Geographic variation in breast cancer incidence and sunlight in the USSR: the possible protective effects of vitamin D3 and 25-hydroxyvitamin D3
AUTHOR(S): Gorham, E. D.; Garland, F. C.; Garland, C. F.
CORPORATE SOURCE: Sch. Med., Univ. California, San Diego, La Jolla, CA, 92093, USA
SOURCE: Biol. Eff. Light, Proc. Symp. (1992), Meeting Date 1991, 68-72. Editor(s): Holick, Michael F.; Kligman, Albert M. de Gruyter: Berlin, Germany.

CODEN: 59NRA6
DOCUMENT TYPE: Conference
LANGUAGE: English

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:417653 CAPLUS
DOCUMENT NUMBER: 109:17653
TITLE: Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells
AUTHOR(S): Koga, Masafumi; Eisman, John A.; Sutherland, Robert L.
CORPORATE SOURCE: Garvan Inst. Med. Res., St. Vincent's Hosp., Sydney, 2010, Australia
SOURCE: Cancer Research (1988), 48(10), 2734-9
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:62812 CAPLUS
DOCUMENT NUMBER: 104:62812
TITLE: Demonstration and characterization of a 1α,25-(dihydroxyvitamin) D3 receptor-like macromolecule in cultured rat pituitary cells
AUTHOR(S): Haug, Egil; Gautvik, Kaare M.
CORPORATE SOURCE: Horm. Lab., Aker Hosp., Oslo, Norway
SOURCE: Journal of Steroid Biochemistry (1985), 23(5A), 625-35
CODEN: JSTBBK; ISSN: 0022-4731
DOCUMENT TYPE: Journal
LANGUAGE: English

=> s (treat? or prevent? or inhibit? or reduc?) and l6
3348121 TREAT?
848549 PREVENT?
1825992 INHIBIT?
2047429 REDUC?
889972 REDN
49161 REDNS
920856 REDN
(REDN OR REDNS)
2552702 REDUC?
(REDUC? OR REDN)
L7 14 (TREAT? OR PREVENT? OR INHIBIT? OR REDUC?) AND L6

=> d ibib 1-7

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:452435 CAPLUS
DOCUMENT NUMBER: 129:131487
TITLE: Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy
AUTHOR(S): Toivonen, Jukka; Tahtela, Riitta; Laitinen, Kalevi; Risteli, Juha; Valimaki, Matti J.
CORPORATE SOURCE: Department of Medicine, Helsinki University Central Hospital, Helsinki, FIN-00290, Finland
SOURCE: European Journal of Endocrinology (1998), 138(6), 667-673
CODEN: EJOEEP; ISSN: 0804-4643
PUBLISHER: BioScientifica
DOCUMENT TYPE: Journal
LANGUAGE: English

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:319281 CAPLUS
DOCUMENT NUMBER: 129:66214
TITLE: Renal tubular reabsorption of phosphate is positively related to the extent of bone metastatic load in patients with prostate cancer
AUTHOR(S): Buchs, Nicolas; Bonjour, Jean-Philippe; Rizzoli, Rene
CORPORATE SOURCE: Division of Bone Diseases, World Health Organization Collaborating Center for Osteoporosis and Bone Diseases, Department of Internal Medicine, University Hospital, Geneva, 1211/14, Switz.
SOURCE: Journal of Clinical Endocrinology and Metabolism (1998), 83(5), 1535-1541
CODEN: JCEMAZ; ISSN: 0021-972X
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:511176 CAPLUS
DOCUMENT NUMBER: 127:185673
TITLE: Effect of clodronate on calcidiol serum levels in women with breast cancer
AUTHOR(S): Martinez, M. E.; Pastrana, P.; Sanchez-Cabezudo, M. J.; Jariego, C.; Del Campo, M. T.
CORPORATE SOURCE: Biochemistry Division, La Paz Hospital, Madrid, 28046, Spain
SOURCE: Calcified Tissue International (1997), 61(2), 148-150
CODEN: CTINDZ; ISSN: 0171-967X
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:688150 CAPLUS
DOCUMENT NUMBER: 123:132206
TITLE: 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1α,25-dihydroxyvitamin D3, **inhibits** azoxymethane-induced colonic tumorigenesis
AUTHOR(S): Wali, Ramesh K.; Bissonnette, Marc; Khare, Sharad; Hart, John; Sitrin, Michael D.; Brasitus, Thomas A.
CORPORATE SOURCE: Dep. of Medicine and Pathology, Univ. of Chicago, Chicago, IL, 60637, USA
SOURCE: Cancer Research (1995), 55(14), 3050-4
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:326434 CAPLUS
DOCUMENT NUMBER: 122:96002
TITLE: Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3
AUTHOR(S): Skowronski, Roman J.; Peehl, Donna M.; Feldman, David

CORPORATE SOURCE: Dep. Med. and Urology (D.M.P.), Stanford Univ. Sch. Med., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1995), 136(1), 20-6
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:554464 CAPLUS
DOCUMENT NUMBER: 121:154464
TITLE: Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line
AUTHOR(S): Mawer, E. Barbara; Hayes, Michael E.; Heys, Sara E.; Davies, Michael; White, Anne; Stewart, M. Felicity; Smith, George N.
CORPORATE SOURCE: Bone Disease Res. Cent., Manchester Univ., Manchester, UK
SOURCE: Journal of Clinical Endocrinology and Metabolism (1994), 79(2), 554-60
CODEN: JCEMAZ; ISSN: 0021-972X
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:183910 CAPLUS
DOCUMENT NUMBER: 120:183910
TITLE: Role of the 75 kD- and 55 kD-receptors in tumor necrosis factor mediated cytotoxicity and its regulation by dexamethasone and by 1,25-dihydroxyvitamin D3 in U937 cells
AUTHOR(S): Chambaut-Guerin, Anne Marie; Guerrier, Maguy; Thomopoulos, Pierre
CORPORATE SOURCE: INSERM U282, Hop. Henri Mondor, Creteil, 94010, Fr.
SOURCE: European Cytokine Network (1993), 4(4), 285-92
CODEN: ECYNEJ; ISSN: 1148-5493
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d ibib 8-14

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:72532 CAPLUS
DOCUMENT NUMBER: 120:72532
TITLE: Geographic variation in breast cancer incidence and sunlight in the USSR: the possible protective effects of vitamin D3 and 25-hydroxyvitamin D3
AUTHOR(S): Gorham, E. D.; Garland, F. C.; Garland, C. F.
CORPORATE SOURCE: Sch. Med., Univ. California, San Diego, La Jolla, CA, 92093, USA
SOURCE: Biol. Eff. Light, Proc. Symp. (1992), Meeting Date 1991, 68-72. Editor(s): Holick, Michael F.; Kligman, Albert M. de Gruyter: Berlin, Germany.
CODEN: 59NRA6
DOCUMENT TYPE: Conference
LANGUAGE: English

L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:417653 CAPLUS
DOCUMENT NUMBER: 109:17653
TITLE: Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer

cells
AUTHOR(S): Koga, Masafumi; Eisman, John A.; Sutherland, Robert L.
CORPORATE SOURCE: Garvan Inst. Med. Res., St. Vincent's Hosp., Sydney, 2010, Australia
SOURCE: Cancer Research (1988), 48(10), 2734-9
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:62812 CAPLUS
DOCUMENT NUMBER: 104:62812
TITLE: Demonstration and characterization of a 1α,25-(dihydroxyvitamin) D3 receptor-like macromolecule in cultured rat pituitary cells
AUTHOR(S): Haug, Egil; Gautvik, Kaare M.
CORPORATE SOURCE: Horm. Lab., Aker Hosp., Oslo, Norway
SOURCE: Journal of Steroid Biochemistry (1985), 23(5A), 625-35
CODEN: JSTBBK; ISSN: 0022-4731
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:613909 CAPLUS
DOCUMENT NUMBER: 103:213909
TITLE: Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells
AUTHOR(S): Costa, Elizabeth M.; Hirst, Margaret A.; Feldman, David
CORPORATE SOURCE: Sch. Med., Stanford Univ., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1985), 117(5), 2203-10
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:80440 CAPLUS
DOCUMENT NUMBER: 100:80440
TITLE: Induction of a high phagocytic capability in P388D1, a macrophage-like tumor cell line, by 1α,25-dihydroxyvitamin D3
AUTHOR(S): Goldman, Rachel
CORPORATE SOURCE: Dep. Membr. Res., Weizmann Inst. Sci., Rehovot, Israel
SOURCE: Cancer Research (1984), 44(1), 11-19
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1982:597201 CAPLUS
DOCUMENT NUMBER: 97:197201
TITLE: Effects of vitamin D metabolites on prolactin and growth hormone synthesis in cultured rat pituitary cells
AUTHOR(S): Haug, E.; Pedersen, J. I.; Gautvik, K.
CORPORATE SOURCE: Inst. Physiol., Univ. Oslo, Oslo, 1, Norway
SOURCE: Proceedings of the Workshop on Vitamin D (1982), 5th(Vitam. D: Chem., Biochem. Clin. Endocrinol. Calcium Metab.), 87-9
CODEN: PWVDDU; ISSN: 0721-7110
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:586523 CAPLUS
DOCUMENT NUMBER: 85:186523
TITLE: 25-Hydroxycholecalciferol and 1,25-dihydroxycholecalciferol are potent **inhibitors** of cholesterol biosynthesis by normal and leukemic (L2C) guinea pig lymphocytes
AUTHOR(S): Philippot, Jean R.; Cooper, Amiel G.; Wallach, D. F. Hoelzl
CORPORATE SOURCE: Ther. Radiol. Dep., Tufts New England Med. Cent., Boston, MA, USA
SOURCE: Biochemical and Biophysical Research Communications (1976), 72(3), 1035-41
CODEN: BBRCA9; ISSN: 0006-291X
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d kwic 11

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . other vitamin D analogs. This phenomenon was also observed in other cell lines, including human skin fibroblasts and human mammary **cancer** cells (MCF-7). **Treatment** with active hormone or vitamin D analogs results in a substantial increase (200-400%) in the number of 1,25-(OH)2D3 receptors without. . . nM and sediments at 3.3S on hypertonic sucrose gradients. In addition, .apprx.50% of the total receptors from both control and **treated** cells bind to DNA-cellulose and elute at 0.18M KCl. These results indicate that the up-regulated receptor is similar to the. . . binding is not a result of differential receptor localization or extractability. 1,25-(OH)2D3, 1,24,25-trihydroxyvitamin D3 [50648-94-7], 24,25-(OH)2D3 [40013-87-4], and 25-hydroxyvitamin D3 [**19356-17-3**] all increase receptor binding to similar levels, and the dose required closely reflects the affinities of the various metabolites for the receptor. **Treatment** of cells with the RNA synthesis **inhibitor** actinomycin D indicates that the increase in receptors is partially dependent on RNA synthesis. Mutant skin fibroblasts from patients with. . .

=> d kwic 14

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
TI 25-Hydroxycholecalciferol and 1,25-dihydroxycholecalciferol are potent **inhibitors** of cholesterol biosynthesis by normal and leukemic (L2C) guinea pig lymphocytes
AB . . . guinea pig lymphocytes was measured. The L2C cells produced I at 25-60 times the rate found with normal cells. 25-Hydroxycholecalciferol [**19356-17-3**] and 1,25-dihydroxycholecalciferol [32511-63-0], both biol. active derivs. of vitamin D3, at submicromolar concns. **inhibited** I biosynthesis by both normal and **neoplastic** lymphocytes. Unoxygenated vitamin D3 [67-97-0] was not **inhibitory**. The rate of **inhibition** due to 25-hydroxycholecalciferol was considerably greater than that of the oxygenated I analogs.
IT Leukemia
(cholesterol formation by, hydroxycholecalciferol **inhibition** of)
IT Lymphocyte
(cholesterol formation in, hydroxycholecalciferol **inhibition** of)
IT 19356-17-3 32511-63-0
RL: BIOL (Biological study)
(cholesterol formation **inhibition** by, in normal and leukemic

lymphocytes)
IT 57-88-5, biological studies
RL: FORM (Formation, nonpreparative)
(formation of, hydroxycholecalciferol **inhibition** of, in normal and leukemic lymphocytes)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.50	61.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

FILE 'REGISTRY' ENTERED AT 07:05:52 ON 02 MAY 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2006 HIGHEST RN 882489-85-2
DICTIONARY FILE UPDATES: 1 MAY 2006 HIGHEST RN 882489-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 19356-17-3/RN

L8 1 19356-17-3/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L8 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **19356-17-3** REGISTRY
CN 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3β,5Z,7E)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,10-Secocholesta-5,7,10(19)-triene-3β,25-diol (8CI)
OTHER NAMES:
CN 25-HCC
CN 25-Hydroxycholecalciferol
CN 25-Hydroxyvitamin D
CN 25-Hydroxyvitamin D3
CN 5,6-cis-25-Hydroxyvitamin D3
CN Calcidiol
CN Calcifediol
CN Calderol
CN Cholecalciferol, 25-hydroxy-
CN Dedrogyl
CN Didrogyl
CN Hidroferol
CN Ro 8-8892
CN U 32070E
FS STEREOSEARCH
DR 25631-40-7
MF C27 H44 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PROMT, PS, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3121 REFERENCES IN FILE CA (1907 TO DATE)
44 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3122 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.66	64.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

FILE 'CAPLUS' ENTERED AT 07:08:17 ON 02 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 May 2006 VOL 144 ISS 19
FILE LAST UPDATED: 1 May 2006 (20060501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

```
http://www.cas.org/infopolicy.html

=> d kwic 8
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n


=> d kwic l7 8

L7   ANSWER 8 OF 14  CAPLUS  COPYRIGHT 2006 ACS on STN
AB   . . . consistent with the general world-wide geog. pattern, and
     supports the possibility that vitamin D3, which is associated with sunlight,
     may inhibit the development of breast cancer.
IT   67-97-0, Vitamin D3 19356-17-3, 25-Hydroxyvitamin D3
     RL: BIOL (Biological study)
        (breast cancer from sunlight in USSR in relation to)


=> file his
'HIS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAPLUS'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> d his

     (FILE 'HOME' ENTERED AT 06:57:47 ON 02 MAY 2006)

     FILE 'REGISTRY' ENTERED AT 06:58:14 ON 02 MAY 2006
                E "25-HYDROXYVITAMIN D"/CN 25
L1             3 S E3

     FILE 'CAPLUS' ENTERED AT 06:59:16 ON 02 MAY 2006
L2          4159 S L1
L3        705552 S CANCER? OR TUMOR? OR NEOPLAS?
L4             1 S L2 (L) L3\
L5            78 S L2 (L) L3
L6            22 S L5 NOT PY>1998
L7            14 S (TREAT? OR PREVENT? OR INHIBIT? OR REDUC?) AND L6

     FILE 'REGISTRY' ENTERED AT 07:05:52 ON 02 MAY 2006
L8             1 S 19356-17-3/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 07:08:17 ON 02 MAY 2006

=> s prostate and l2
         45911 PROSTATE
          1321 PROSTATES
         46019 PROSTATE
                 (PROSTATE OR PROSTATES)
L9          57 PROSTATE AND L2

=>  s l9 and l3
L10         53 L9 AND L3

=> s l10 not py>1998
       7447350 PY>1998
L11          5 L10 NOT PY>1998

=> d ibib 1-5
```

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:747235 CAPLUS
DOCUMENT NUMBER: 130:137480
TITLE: Severe, diffuse osteosclerosis: a new manifestation of transitional cell carcinoma of the urinary bladder
AUTHOR(S): Liel, Y.; Maor, E.; Ariad, S.; Lowenthal, M. N.
CORPORATE SOURCE: Bone and Mineral Metabolism and Endocrine Units, Ben-Gurion University of the Negev, Beer Sheva, Israel
SOURCE: Calcified Tissue International (1998), 63(6), 471-474
CODEN: CTINDZ; ISSN: 0171-967X
PUBLISHER: Springer-Verlag New York Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:349649 CAPLUS
DOCUMENT NUMBER: 129:104679
TITLE: Human **prostate** cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3
AUTHOR(S): Schwartz, Gary G.; Whitlatch, Lyman W.; Chen, Tai C.; Lokeshwar, Bal L.; Holick, Michael F.
CORPORATE SOURCE: Sylvester Comprehensive Cancer Center and Department of Epidemiology & Public Health, University of Miami School of Medicine, Miami, FL, 33101, USA
SOURCE: Cancer Epidemiology, Biomarkers & Prevention (1998), 7(5), 391-395
CODEN: CEBPE4; ISSN: 1055-9965
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:319281 CAPLUS
DOCUMENT NUMBER: 129:66214
TITLE: Renal tubular reabsorption of phosphate is positively related to the extent of bone metastatic load in patients with **prostate cancer**
AUTHOR(S): Buchs, Nicolas; Bonjour, Jean-Philippe; Rizzoli, Rene
CORPORATE SOURCE: Division of Bone Diseases, World Health Organization Collaborating Center for Osteoporosis and Bone Diseases, Department of Internal Medicine, University Hospital, Geneva, 1211/14, Switz.
SOURCE: Journal of Clinical Endocrinology and Metabolism (1998), 83(5), 1535-1541
CODEN: JCEMAZ; ISSN: 0021-972X
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:706195 CAPLUS
DOCUMENT NUMBER: 123:161606
TITLE: Actions of 1,25-dihydroxyvitamin D and synthetic analogs on cultured human **prostate** carcinoma cells
AUTHOR(S): Skowronski, Roman J.; Peehl, Donna M.; Cramer, Scott;

Feldman, David
CORPORATE SOURCE: School Medicine, Stanford University, Stanford, CA, 94305, USA
SOURCE: Proceedings of the Workshop on Vitamin D (1994), 9th(Vitamin D), 520-1
CODEN: PWVDDU; ISSN: 0721-7110
PUBLISHER: de Gruyter
DOCUMENT TYPE: Journal
LANGUAGE: English

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:326434 CAPLUS
DOCUMENT NUMBER: 122:96002
TITLE: Actions of vitamin D3 analogs on human **prostate cancer** cell lines: comparison with 1,25-dihydroxyvitamin D3
AUTHOR(S): Skowronski, Roman J.; Peehl, Donna M.; Feldman, David
CORPORATE SOURCE: Dep. Med. and Urology (D.M.P.), Stanford Univ. Sch. Med., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1995), 136(1), 20-6
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d kwic 4-5

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Actions of 1,25-dihydroxyvitamin D and synthetic analogs on cultured human **prostate** carcinoma cells
AB It is shown that benign and malignant human **prostate** carcinoma cells possess VDR and that 1,25-dihydroxyvitamin D treatment can elicit an antiproliferative action in these cells. Although binding to. . . exhibit less calcemic activity than 1,25-dihydroxyvitamin D, may indicate their pot. use as an addnl. therapeutic option for treatment of **prostate cancer**.
ST calcitriol analog **prostate** carcinoma
IT **Prostate** gland
(**neoplasm**, carcinoma, calcitriol and synthetic analogs effect on cultured human **prostate** carcinoma cells)
IT **Prostate** gland
(**neoplasm**, carcinoma, inhibitors, calcitriol and synthetic analogs effect on cultured human **prostate** carcinoma cells)
IT **Neoplasm** inhibitors
(**prostate** gland carcinoma, calcitriol and synthetic analogs effect on cultured human **prostate** carcinoma cells)
IT Receptors
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(vitamin D, calcitriol and synthetic analogs effect on cultured human **prostate** carcinoma cells)
IT 53112-53-1, 25-Hydroxyvitamin D3 24-hydroxylase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calcitriol and synthetic analogs effect on cultured human **prostate** carcinoma cells)
IT **19356-17-3**, 25-Hydroxyvitamin D3 32222-06-3, Calcitriol 32222-06-3D, Calcitriol, analogs 50648-94-7, 1,24,25-Trihydroxyvitamin D3 83150-76-9, Octreotide 112965-21-6, MC 903 124409-58-1 134404-52-7, EB 1089
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(calcitriol and synthetic analogs effect on cultured human **prostate** carcinoma cells)

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Actions of vitamin D3 analogs on human **prostate cancer** cell lines: comparison with 1,25-dihydroxyvitamin D3
AB Data from epidemiol. studies has suggested that vitamin D deficiency may promote **prostate cancer**, although the mechanism is not understood. The authors have previously demonstrated the presence of vitamin D receptors (VDR) in three human **prostate** carcinoma cell lines (LNCaP, PC-3, and DU-145) as well as in primary cultures of stromal and epithelial cells derived from normal and malignant **prostate** tissues. The authors have also shown that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] can elicit an antiproliferative action in these cells. In the. . . of vitamin D3 metabolites and analogs to inhibit cell proliferation correlated well with the ability of these compds. to stimulate **prostate**-specific antigen secretion by LNCaP cells as well as with their potency to induce the 25-hydroxyvitamin D3-24-hydroxylase mRNA transcript in PC-3. . . activity than 1,25-(OH)2D3 suggest that these compds. potentially may be useful as an addnl. therapeutic option for the treatment of **prostate cancer**.
ST vitamin D3 analog **prostate cancer**
IT **Neoplasm** inhibitors
(vitamin D3 analog effects on human **prostate cancer** cell lines in comparison with 1,25-dihydroxyvitamin D3)
IT Antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PSA (**prostate**-specific antigen), vitamin D3 analog effects on human **prostate cancer** cell lines in comparison with 1,25-dihydroxyvitamin D3)
IT **Prostate** gland
(**neoplasm**, vitamin D3 analog effects on human **prostate cancer** cell lines in comparison with 1,25-dihydroxyvitamin D3)
IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vitamin D, vitamin D3 analog effects on human **prostate cancer** cell lines in comparison with 1,25-dihydroxyvitamin D3)
IT 67-97-0D, Vitamin D3, analogs **19356-17-3**, 25-Hydroxyvitamin D3 32222-06-3, Calcitriol 50648-94-7, 1,24,25-Trihydroxy vitamin D3 103909-75-7, 22-Oxacalcitriol 112965-21-6, MC-903 124409-58-1 124409-59-2, 9,10-Secocholesta-5,7,10(19),16,23-pentaene-3,25-diol, (3β,5Z,7E,23E)- 134404-52-7, EB-1089
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D3 analog effects on human **prostate cancer** cell lines in comparison with 1,25-dihydroxyvitamin D3)
IT 53112-53-1, 25-Hydroxyvitamin D3-24-hydroxylase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vitamin D3 analog effects on human **prostate cancer** cell lines in comparison with 1,25-dihydroxyvitamin D3)

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.69	82.60

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -2.25      -3.75

FILE 'PCTFULL' ENTERED AT 07:11:28 ON 02 MAY 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:          2 MAY 2006      <20060502/UP>
MOST RECENT UPDATE WEEK:       200617        <200617/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
    SEE
    http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
    (last updated April 10, 2006) <<<

=> s 25-hydroxyvitamin D? or calcidiol or calcifediol or calderol or dedrogyl or
didrogyl or hidroferol or (RO 8-8892) or (U 32070E)

<------User Break------>

SEARCH ENDED BY USER

=> s 25-hydroxyvitamin D? or calcidiol or calcifediol or calderol or dedrogyl or
didrogyl or hidroferol or (RO 8-8892) or (U 32070E)

<------User Break------>

SEARCH ENDED BY USER

=> file pctfull
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   5.80      88.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -3.75

FILE 'PCTFULL' ENTERED AT 07:14:33 ON 02 MAY 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:          2 MAY 2006      <20060502/UP>
MOST RECENT UPDATE WEEK:       200617        <200617/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
    SEE
    http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
    (last updated April 10, 2006) <<<

=> s 25-hydroxyvitamin D? or calcidiol or calcifediol or calderol

<------User Break------>
```

SEARCH ENDED BY USER

=> s 25-hydroxyvitamin D?
<------User Break------>

SEARCH ENDED BY USER

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW

Thank you in advance for your participation.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:55:16 ON 02 MAY 2006

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 10:55:27 ON 02 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 May 2006 VOL 144 ISS 19
FILE LAST UPDATED: 1 May 2006 (20060501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 19356-17-3
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

```
L2        3122 L1


=> s cancer? or tumor? or neoplas?
         291257 CANCER?
         426036 TUMOR?
         447058 NEOPLAS?
L3       705552 CANCER? OR TUMOR? OR NEOPLAS?

=> s l2 (l) l3
L4           59 L2 (L) L3

=> s l4 not py>1998
        7447350 PY>1998
L5           21 L4 NOT PY>1998

=> s inhibit? or treat? or prevent? or reduc?
        1825992 INHIBIT?
        3348121 TREAT?
         848549 PREVENT?
        2047429 REDUC?
         889972 REDN
          49161 REDNS
         920856 REDN
                (REDN OR REDNS)
        2552702 REDUC?
                (REDUC? OR REDN)
L6      6877201 INHIBIT? OR TREAT? OR PREVENT? OR REDUC?
 75% OF LIMIT FOR TOTAL ANSWERS REACHED

=> s (inhibit? or treat? or prevent? or reduc?) and l5
        1825992 INHIBIT?
        3348121 TREAT?
         848549 PREVENT?
        2047429 REDUC?
         889972 REDN
          49161 REDNS
         920856 REDN
                (REDN OR REDNS)
        2552702 REDUC?
                (REDUC? OR REDN)
L7           13 (INHIBIT? OR TREAT? OR PREVENT? OR REDUC?) AND L5

=> d ibib 1-7

L7   ANSWER 1 OF 13  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1998:452435  CAPLUS
DOCUMENT NUMBER:          129:131487
TITLE:                    Markers of bone turnover in patients with
                          differentiated thyroid cancer with and following
                          withdrawal of thyroxine suppressive therapy
AUTHOR(S):                Toivonen, Jukka; Tahtela, Riitta; Laitinen, Kalevi;
                          Risteli, Juha; Valimaki, Matti J.
CORPORATE SOURCE:         Department of Medicine, Helsinki University Central
                          Hospital, Helsinki, FIN-00290, Finland
SOURCE:                   European Journal of Endocrinology (1998), 138(6),
                          667-673
                          CODEN: EJOEEP; ISSN: 0804-4643
PUBLISHER:                BioScientifica
```

DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:511176 CAPLUS
DOCUMENT NUMBER: 127:185673
TITLE: Effect of clodronate on calcidiol serum levels in women with breast cancer
AUTHOR(S): Martinez, M. E.; Pastrana, P.; Sanchez-Cabezudo, M. J.; Jariego, C.; Del Campo, M. T.
CORPORATE SOURCE: Biochemistry Division, La Paz Hospital, Madrid, 28046, Spain
SOURCE: Calcified Tissue International (1997), 61(2), 148-150
CODEN: CTINDZ; ISSN: 0171-967X
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:688150 CAPLUS
DOCUMENT NUMBER: 123:132206
TITLE: 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1α,25-dihydroxyvitamin D3, **inhibits** azoxymethane-induced colonic tumorigenesis
AUTHOR(S): Wali, Ramesh K.; Bissonnette, Marc; Khare, Sharad; Hart, John; Sitrin, Michael D.; Brasitus, Thomas A.
CORPORATE SOURCE: Dep. of Medicine and Pathology, Univ. of Chicago, Chicago, IL, 60637, USA
SOURCE: Cancer Research (1995), 55(14), 3050-4
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:326434 CAPLUS
DOCUMENT NUMBER: 122:96002
TITLE: Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3
AUTHOR(S): Skowronski, Roman J.; Peehl, Donna M.; Feldman, David
CORPORATE SOURCE: Dep. Med. and Urology (D.M.P.), Stanford Univ. Sch. Med., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1995), 136(1), 20-6
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:554464 CAPLUS
DOCUMENT NUMBER: 121:154464
TITLE: Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line
AUTHOR(S): Mawer, E. Barbara; Hayes, Michael E.; Heys, Sara E.; Davies, Michael; White, Anne; Stewart, M. Felicity; Smith, George N.
CORPORATE SOURCE: Bone Disease Res. Cent., Manchester Univ., Manchester, UK

SOURCE: Journal of Clinical Endocrinology and Metabolism (1994), 79(2), 554-60
CODEN: JCEMAZ; ISSN: 0021-972X
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:183910 CAPLUS
DOCUMENT NUMBER: 120:183910
TITLE: Role of the 75 kD- and 55 kD-receptors in tumor necrosis factor mediated cytotoxicity and its regulation by dexamethasone and by 1,25-dihydroxyvitamin D3 in U937 cells
AUTHOR(S): Chambaut-Guerin, Anne Marie; Guerrier, Maguy; Thomopoulos, Pierre
CORPORATE SOURCE: INSERM U282, Hop. Henri Mondor, Creteil, 94010, Fr.
SOURCE: European Cytokine Network (1993), 4(4), 285-92
CODEN: ECYNEJ; ISSN: 1148-5493
DOCUMENT TYPE: Journal
LANGUAGE: English

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:72532 CAPLUS
DOCUMENT NUMBER: 120:72532
TITLE: Geographic variation in breast cancer incidence and sunlight in the USSR: the possible protective effects of vitamin D3 and 25-hydroxyvitamin D3
AUTHOR(S): Gorham, E. D.; Garland, F. C.; Garland, C. F.
CORPORATE SOURCE: Sch. Med., Univ. California, San Diego, La Jolla, CA, 92093, USA
SOURCE: Biol. Eff. Light, Proc. Symp. (1992), Meeting Date 1991, 68-72. Editor(s): Holick, Michael F.; Kligman, Albert M. de Gruyter: Berlin, Germany.
CODEN: 59NRA6
DOCUMENT TYPE: Conference
LANGUAGE: English

=> d ibib abs kwic 3-4

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:688150 CAPLUS
DOCUMENT NUMBER: 123:132206
TITLE: 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1α,25-dihydroxyvitamin D3, **inhibits** azoxymethane-induced colonic tumorigenesis
AUTHOR(S): Wali, Ramesh K.; Bissonnette, Marc; Khare, Sharad; Hart, John; Sitrin, Michael D.; Brasitus, Thomas A.
CORPORATE SOURCE: Dep. of Medicine and Pathology, Univ. of Chicago, Chicago, IL, 60637, USA
SOURCE: Cancer Research (1995), 55(14), 3050-4
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Vitamin D3 and its metabolites, particularly 1α25-dihydroxyvitamin D3 (1α, 25(OH)2D3), have received increasing attention as potential anticarcinogens in the **prevention** of cancers in a number of organs, including the colon. These agents however have the potential to induce hypercalcemia, thus limiting their practical use for these purposes. In the present studies it was, therefore, of interest to determine whether dietary supplementation with 1α,25-dihydroxy-16-ene-23-yne-26,27-

hexafluorocholecalciferol (RO24-5531), a recently synthesized apparently noncalcemic analog of 1α,25(OH)2D3, **inhibited** colon cancer induced by azoxymethane (AOM). Rats were placed on a standard diet or fed this diet with supplemental RO24-5531 (2.5 nmol/kg feed) before and during (initiation arm), or after AOM or vehicle administration (postinitiation arm). After 34 wk of study, animals in each group were sacrificed, and their colons were removed and examined macroscopically and microscopically for the presence of tumors. At the time of sacrifice, the animals' serum calcium, phosphorus, 25-hydroxyvitamin D3 and 1α,25(OH)2D3 levels were also analyzed. The results of these studies demonstrated that dietary RO24-5531 supplementation during the initiation arm of these expts. significantly **reduced** (by 70%) the incidence of AOM-induced colonic tumors compared to rats on the standard diet without RO24-5531. Moreover, this dietary regimen abolished the development of adenocarcinomas in this model. Although there was also a trend for dietary RO24-5531 supplementation during the postinitiation arm of this study to **reduce** the incidence of colon tumors, this did not reach statistical significance ($P > 0.05$). In addition, neither dietary RO24-5531 supplementation regimen significantly influenced the animals' rates of growth or their serum levels of calcium, phosphorus, or 25-hydroxyvitamin D3. These studies, therefore, demonstrate for the first time that supplemental dietary RO24-5531 is a chemopreventive agent in the AOM model of exptl. colonic carcinogenesis. They also suggest that this agent may ultimately prove useful in clin. colon cancer chemopreventive trials.

TI 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1α,25-dihydroxyvitamin D3, **inhibits** azoxymethane-induced colonic tumorigenesis

AB Vitamin D3 and its metabolites, particularly 1α25-dihydroxyvitamin D3 (1α, 25(OH)2D3), have received increasing attention as potential anticarcinogens in the **prevention** of cancers in a number of organs, including the colon. These agents however have the potential to induce hypercalcemia, thus limiting their practical use for these purposes. In the present studies it was, therefore, of interest to determine whether dietary supplementation with 1α,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (RO24-5531), a recently synthesized apparently noncalcemic analog of 1α,25(OH)2D3, **inhibited** colon cancer induced by azoxymethane (AOM). Rats were placed on a standard diet or fed this diet with supplemental RO24-5531 (2.5 nmol/kg feed) before and during (initiation arm), or after AOM or vehicle administration (postinitiation arm). After 34 wk of study, animals in each group were sacrificed, and their colons were removed and examined macroscopically and microscopically for the presence of tumors. At the time of sacrifice, the animals' serum calcium, phosphorus, 25-hydroxyvitamin D3 and 1α,25(OH)2D3 levels were also analyzed. The results of these studies demonstrated that dietary RO24-5531 supplementation during the initiation arm of these expts. significantly **reduced** (by 70%) the incidence of AOM-induced colonic tumors compared to rats on the standard diet without RO24-5531. Moreover, this dietary regimen abolished the development of adenocarcinomas in this model. Although there was also a trend for dietary RO24-5531 supplementation during the postinitiation arm of this study to **reduce** the incidence of colon tumors, this did not reach statistical significance ($P > 0.05$). In addition, neither dietary RO24-5531 supplementation regimen significantly influenced the animals' rates of growth or their serum levels of calcium, phosphorus, or 25-hydroxyvitamin D3. These studies, therefore, demonstrate for the first time that supplemental dietary RO24-5531 is a chemopreventive agent in the AOM model of exptl. colonic carcinogenesis. They also suggest that this agent may ultimately prove useful in clin. colon cancer chemopreventive trials.

IT Neoplasm **inhibitors**
(colon carcinoma, RO24-5531 **inhibition** of colonic tumorigenesis as noncalcemic analog of 1α,25-dihydroxyvitamin D3)

IT Intestine, neoplasm
(colon, carcinoma, **inhibitors**, RO24-5531 **inhibition** of colonic tumorigenesis as noncalcemic analog of 1α,25-dihydroxyvitamin D3)

IT 137102-93-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RO24-5531 **inhibition** of colonic tumorigenesis as noncalcemic analog of 1α,25-dihydroxyvitamin D3)

IT 7440-70-2, Calcium, biological studies 7723-14-0, Phosphorus, biological studies **19356-17-3**, 25-Hydroxyvitamin D3 32222-06-3, 1α,25(OH)2D3
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RO24-5531 **inhibition** of colonic **tumorigenesis** as noncalcemic analog of 1α,25-dihydroxyvitamin D3)

L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:326434 CAPLUS
DOCUMENT NUMBER: 122:96002
TITLE: Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3
AUTHOR(S): Skowronski, Roman J.; Peehl, Donna M.; Feldman, David
CORPORATE SOURCE: Dep. Med. and Urology (D.M.P.), Stanford Univ. Sch. Med., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1995), 136(1), 20-6
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Data from epidemiol. studies has suggested that vitamin D deficiency may promote prostate cancer, although the mechanism is not understood. The authors have previously demonstrated the presence of vitamin D receptors (VDR) in three human prostate carcinoma cell lines (LNCaP, PC-3, and DU-145) as well as in primary cultures of stromal and epithelial cells derived from normal and malignant prostate tissues. The authors have also shown that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] can elicit an antiproliferative action in these cells. In the present study the authors compared the biol. actions of 1,25-(OH)2D3 to those of a series of natural vitamin D3 metabolites and several synthetic analogs of vitamin D3 known to exhibit less hypercalcemic activity in vivo. In ligand binding competition expts., the authors demonstrated the following order of potency in displacing [3H]1,25-(OH)2D3 from VDR: EB-1089 > 1,25-(OH)2D3 > MC-903 > 1,24,25(OH)3D3 > 22-oxacalcitriol (OCT) > 1α,25-dihydroxy-16-ene-cholecalciferol (Ro 24-2637) > 25-hydroxyvitamin D3, with EB-1089 being .apprx.2-fold more potent than the native hormone. No competitive activity was found for 25-hydroxy-16,23-diene-cholecalciferol. When compared for ability to **inhibit** proliferation of LNCaP cells, MC-903, EB-1089, OCT, and Ro 24-2637 exhibited 4-, 3-, 3-, and 2-fold greater **inhibitory** activity than 1,25-(OH)2D3. Interestingly, although OCT and Ro 24-2637 exhibit, resp., 10 and 14 times lower affinity for VDR than 1,25-(OH)2D3, both compds. **inhibited** the proliferation of LNCaP cells with a potency greater than that of the native hormone. The relative potency of vitamin D3 metabolites and analogs to **inhibit** cell proliferation correlated well with the ability of these compds. to stimulate prostate-specific antigen secretion by LNCaP cells as well as with their potency to induce the 25-hydroxyvitamin D3-24-hydroxylase mRNA transcript in PC-3 cells. In conclusion, these results demonstrate that synthetic analogs of vitamin D3, known to exhibit **reduced** calcemic activity, can elicit antiproliferative effects and other biol. actions in LNCaP and PC-3 cell lines. It is noteworthy that although binding to VDR is critical for

1,25-(OH)2D3 action, the analog data indicate that addnl. factors significantly contribute to the magnitude of the biol. response. Finally, the strong antiproliferative effects of several synthetic analogs known to exhibit less calcemic activity than 1,25-(OH)2D3 suggest that these compds. potentially may be useful as an addnl. therapeutic option for the **treatment** of prostate cancer.

AB Data from epidemiol. studies has suggested that vitamin D deficiency may promote prostate cancer, although the mechanism is not understood. The authors have previously demonstrated the presence of vitamin D receptors (VDR) in three human prostate carcinoma cell lines (LNCaP, PC-3, and DU-145) as well as in primary cultures of stromal and epithelial cells derived from normal and malignant prostate tissues. The authors have also shown that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] can elicit an antiproliferative action in these cells. In the present study the authors compared the biol. actions of 1,25-(OH)2D3 to those of a series of natural vitamin D3 metabolites and several synthetic analogs of vitamin D3 known to exhibit less hypercalcemic activity in vivo. In ligand binding competition expts., the authors demonstrated the following order of potency in displacing [3H]1,25-(OH)2D3 from VDR: EB-1089 > 1,25-(OH)2D3 > MC-903 > 1,24,25(OH)3D3 > 22-oxacalcitriol (OCT) > 1α,25-dihydroxy-16-ene-cholecalciferol (Ro 24-2637) > 25-hydroxyvitamin D3, with EB-1089 being .apprx.2-fold more potent than the native hormone. No competitive activity was found for 25-hydroxy-16,23-diene-cholecalciferol. When compared for ability to **inhibit** proliferation of LNCaP cells, MC-903, EB-1089, OCT, and Ro 24-2637 exhibited 4-, 3-, 3-, and 2-fold greater **inhibitory** activity than 1,25-(OH)2D3. Interestingly, although OCT and Ro 24-2637 exhibit, resp., 10 and 14 times lower affinity for VDR than 1,25-(OH)2D3, both compds. **inhibited** the proliferation of LNCaP cells with a potency greater than that of the native hormone. The relative potency of vitamin D3 metabolites and analogs to **inhibit** cell proliferation correlated well with the ability of these compds. to stimulate prostate-specific antigen secretion by LNCaP cells as well as with their potency to induce the 25-hydroxyvitamin D3-24-hydroxylase mRNA transcript in PC-3 cells. In conclusion, these results demonstrate that synthetic analogs of vitamin D3, known to exhibit **reduced** calcemic activity, can elicit antiproliferative effects and other biol. actions in LNCaP and PC-3 cell lines. It is noteworthy that although binding to VDR is critical for 1,25-(OH)2D3 action, the analog data indicate that addnl. factors significantly contribute to the magnitude of the biol. response. Finally, the strong antiproliferative effects of several synthetic analogs known to exhibit less calcemic activity than 1,25-(OH)2D3 suggest that these compds. potentially may be useful as an addnl. therapeutic option for the **treatment** of prostate cancer.

IT Neoplasm **inhibitors**
(vitamin D3 analog effects on human prostate cancer cell lines in comparison with 1,25-dihydroxyvitamin D3)

IT 67-97-0D, Vitamin D3, analogs **19356-17-3**, 25-Hydroxyvitamin D3 32222-06-3, Calcitriol 50648-94-7, 1,24,25-Trihydroxy vitamin D3 103909-75-7, 22-Oxacalcitriol 112965-21-6, MC-903 124409-58-1 124409-59-2, 9,10-Secocholesta-5,7,10(19),16,23-pentaene-3,25-diol, (3β,5Z,7E,23E)- 134404-52-7, EB-1089
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D3 analog effects on human prostate **cancer** cell lines in comparison with 1,25-dihydroxyvitamin D3)

=> d ibib abs kwic 5

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:554464 CAPLUS

DOCUMENT NUMBER: 121:154464
TITLE: Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line
AUTHOR(S): Mawer, E. Barbara; Hayes, Michael E.; Heys, Sara E.; Davies, Michael; White, Anne; Stewart, M. Felicity; Smith, George N.
CORPORATE SOURCE: Bone Disease Res. Cent., Manchester Univ., Manchester, UK
SOURCE: Journal of Clinical Endocrinology and Metabolism (1994), 79(2), 554-60
CODEN: JCEMAZ; ISSN: 0021-972X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB One of 16 human small cell lung cancer cell lines examined was shown to synthesize a metabolite resembling 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. The NCI H82 line converted 25-hydroxyvitamin D3 (25OHD3) into a compound indistinguishable from 1,25-(OH)2D3 in 3 different high performance liquid chromatog. systems. Electron impact mass spectra for the trimethylsilylethers of the metabolite and authentic 1,25-(OH)2D3 were indistinguishable. Binding to an anti-1,25-(OH)2D3 antibody was identical for the metabolite and authentic 1,25-(OH)2D3, whereas administration to rats in vivo caused equivalent stimulation of calcium transport measured in vitro in duodenal sacs. Activity of the H82 1α-hydroxylase appears to be substrate dependent and is not stimulated by PTH, suggesting that it is similar to the enzyme expressed by activated macrophages and other cell types at extrarenal sites. **Inhibition** by ketoconazole indicates that, like the renal and extrarenal enzymes, the H82 enzyme is cytochrome P 450 dependent. These data indicate that the H82 small cell lung cancer cell line constitutively expresses 25-hydroxyvitamin D3-1α-hydroxylase and can synthesize 1,25-(OH)2D3.

AB One of 16 human small cell lung cancer cell lines examined was shown to synthesize a metabolite resembling 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. The NCI H82 line converted 25-hydroxyvitamin D3 (25OHD3) into a compound indistinguishable from 1,25-(OH)2D3 in 3 different high performance liquid chromatog. systems. Electron impact mass spectra for the trimethylsilylethers of the metabolite and authentic 1,25-(OH)2D3 were indistinguishable. Binding to an anti-1,25-(OH)2D3 antibody was identical for the metabolite and authentic 1,25-(OH)2D3, whereas administration to rats in vivo caused equivalent stimulation of calcium transport measured in vitro in duodenal sacs. Activity of the H82 1α-hydroxylase appears to be substrate dependent and is not stimulated by PTH, suggesting that it is similar to the enzyme expressed by activated macrophages and other cell types at extrarenal sites. **Inhibition** by ketoconazole indicates that, like the renal and extrarenal enzymes, the H82 enzyme is cytochrome P 450 dependent. These data indicate that the H82 small cell lung cancer cell line constitutively expresses 25-hydroxyvitamin D3-1α-hydroxylase and can synthesize 1,25-(OH)2D3.

IT **19356-17-3**, 25-Hydroxyvitamin D3
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of, by human small cell lung **cancer** cell line)

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	47.60	48.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

FILE 'PCTFULL' ENTERED AT 11:02:30 ON 02 MAY 2006

```
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:         2 MAY 2006      <20060502/UP>
MOST RECENT UPDATE WEEK:       200617        <200617/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
    SEE
    http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
    (last updated April 10, 2006) <<<

=> s calcidiol or calcifediol of calderol
            17 CALCIDIOL
            99 CALCIFEDIOL
       1096011 OF
           697 OFS
       1096020 OF
                  (OF OR OFS)
             3 CALDEROL
             0 CALCIFEDIOL OF CALDEROL
                  (CALCIFEDIOL(W)OF(W)CALDEROL)
L8          17 CALCIDIOL OR CALCIFEDIOL OF CALDEROL

=> s cancer? or tumor? or neoplas?
         77789 CANCER?
         65076 TUMOR?
         22573 NEOPLAS?
L9       96951 CANCER? OR TUMOR? OR NEOPLAS?

=> s l8 and l9
L10         17 L8 AND L9

=> s l10 not py>1998
        742760 PY>1998
L11          5 L10 NOT PY>1998

=> d ibib 1-5

L11    ANSWER 1 OF 5     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        1997049815 PCTFULL  ED 20020514
TITLE (ENGLISH):         RETINOID METABOLIZING PROTEIN
TITLE (FRENCH):          PROTEINES METABOLISANT LE RETINOIDE
INVENTOR(S):             PETKOVICH, P., Martin;
                         WHITE, Jay, A.;
                         BECKETT, Barbara, R.;
                         JONES, Glenville
PATENT ASSIGNEE(S):      QUEEN'S UNIVERSITY AT KINGSTON;
                         PETKOVICH, P., Martin;
                         WHITE, Jay, A.;
                         BECKETT, Barbara, R.;
                         JONES, Glenville
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         ---------------------------------
                         WO 9749815           A1 19971231
DESIGNATED STATES
       W:                AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
```

ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS MW
SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-CA440 A 19970623
PRIORITY INFO.: US 1996-8/667,546 19960621
US 1996-8/724,466 19961001

L11 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1995017363 PCTFULL ED 20020514
TITLE (ENGLISH): PALLADIUM CATALYZED ALKYLATIVE CYCLIZATION USEFUL IN SYNTHESES OF VITAMIN D AND ANALOGUES
TITLE (FRENCH): CYCLISATION ALKYLANTE CATALYSEE AVEC DU PALLADIUM UTILE POUR EFFECTUER LA SYNTHESE CHIMIQUE DE LA VITAMINE D ET DE SES ANALOGUES
INVENTOR(S): TROST, Barry, M.;
DUMAS, Jacques
PATENT ASSIGNEE(S): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9517363	A1	19950629

DESIGNATED STATES
W: JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1994-US14634 A 19941219
PRIORITY INFO.: US 1993-8/173,172 19931223

L11 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1994006435 PCTFULL ED 20020513
TITLE (ENGLISH): METHOD OF TREATING PREMENSTRUAL SYNDROME SYMPTOMATOLOGY WITH VITAMIN D OR VITAMIN D AND CALCIUM
TITLE (FRENCH): PROCEDE DE TRAITEMENT DE LA SYMPTOMATOLOGIE DU SYNDROME PREMENSTRUEL PAR LA VITAMINE D OU LA VITAMINE D ET LE CALCIUM COMBINES
INVENTOR(S): THYS-JACOBS, Susan
PATENT ASSIGNEE(S): THYS-JACOBS, Susan
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9406435	A1	19940331

DESIGNATED STATES
W: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1993-US8653 A 19930914
PRIORITY INFO.: US 1992-945,319 19920915
US 1993-59,682 19930510

L11 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1993016022 PCTFULL ED 20020513
TITLE (ENGLISH): PALLADIUM CATALYZED ALKYLATIVE CYCLIZATION USEFUL IN SYNTHESIS OF VITAMIN D AND ANALOGUES
TITLE (FRENCH): CYCLISATION A ALKYLATION CATALYSEE PAR PALLADIUM UTILISEE POUR LA SYNTHESE DE VITAMINE D ET D'ANALOGUES
INVENTOR(S): TROST, Barry, M.;
DUMAS, Jacques
PATENT ASSIGNEE(S): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9316022	A1	19930819

DESIGNATED STATES
W: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1993-US1059 A 19930205
PRIORITY INFO.: US 1992-7/831,687 19920205

L11 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1992021670 PCTFULL ED 20020513
TITLE (ENGLISH): NEW BIOTENSIDE ESTER AND PHOSPHATIDE WITH VITAMIN D AND VITAMIN E COMPOUNDS; THEIR PREPARATION AND TRANSFORMATION INTO SPONTANEOUSLY DISPERSIBLE CONCENTRATES AND THEIR USE FOR TREATING **TUMORS**
TITLE (FRENCH): NOUVEAUX ESTERS ET PHOSPHOLIPIDES BIOTENSIOACTIFS AVEC DES COMPOSES DE VITAMINES D ET DE VITAMINE E; LEUR PREPARATION ET LEUR TRAITEMENT POUR LA FORMATION DE CONCENTRES SUSCEPTIBLES DE SE DISPERSER SPONTANEMENT, AINSI QUE LEUR UTILISATION DANS LA THERAPIE DE TUMEURS
INVENTOR(S): EUGSTER, Carl;
EUGSTER, Conrad, Hans;
HALDEMANN, Walter;
RIVARA, Giorgio
PATENT ASSIGNEE(S): MARIGEN S.A., RIEHEN;
EUGSTER, Carl;
EUGSTER, Conrad, Hans;
HALDEMANN, Walter;
RIVARA, Giorgio
LANGUAGE OF PUBL.: German
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9221670	A1	19921210

DESIGNATED STATES
W: AT BE CH DE DK ES FR GB GR IT JP LU MC NL SE US
APPLICATION INFO.: WO 1992-CH72 A 19920416
PRIORITY INFO.: CH 1991-1662/91-0 19910604

=> d kwic 1

L11 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD Early studies of retinol deficiency indicated a correlation between vitamin A
depletion and a higher incidence of **cancer** and increased susceptability to chemical
carcinogenesis [Chytil, 1984]. Several animal models have been used to demonstrate the
5 effectiveness of refinoids in. . .
. . .
and
basal cell carcinomas [Hong, 1994; Lippman, 1995]. RA itself has been found to be useful
therapeutically, notably in the treatment of **cancers**, including acute promyelocytic leukemia
(APL), **tumors** of the head and neck, and skin **cancer**, as well as in the treatment of skin
disorders such as the premalignancy associated actinic keratoses, acne,

psoriasis and
ichthyosis. There is. . .

RA metabolism may also account for the lack of response of certain **tumors** to
1 0 RA treatment. For example, recent studies have shown that cytochrome P450 inhibitors that
block RA metabolism, resulting in increased tissue levels of RA, may be useful therapeutic
agents in the treatment of prostate **cancer** [Wouters, 1992; De Coster, 1996). Thus RA
metabolizing cytochrome P450s may be useful targets for the treatment of a number of
different types of **cancer**.

. . .
identified as SEQ ID NO:5. The organism can be human
and/or the organism can be in need of treatment against a **cancerous** disease or a disease
selected from the group consisting of **cancer**, actinic
keratosis, oral leukoplakia, a secondary
tumor of the head and/or neck, a non-small cell lung
carcinoma, a basal cell carcinoma, acute
promyelocytic leukemia, skin **cancer**, and a premalignancy
associated actinic keratosis, acne,
psoriasis andlor ichthyosis. Such a method can include use of at least
one delivery. . . length may be found, The organism may be a human patient and
the method can include treating the patent against a **cancerous** disease.

. . .
for P450RAI are useful, for example,
for diagnostic purposes such as for determining P450RAI protein levels in the identification of
normal and **tumor** tissues which metabolize RA. To produce these antibodies, purified
P450RAI protein is prepared. The human P450RAI protein is produced in bacterial. . .

. . .
RA treatment in cell culture and in tissues. P450RAI protein
expression may be a prognostic indicator for determining whether a particular **tumor** will
25 respond to RA treatment. There is also a wide intersubject variability in baseline RA
metabolism and there is evidence suggesting that subjects with a high rate of RA metabolism
have a higher incidence of squamous or large cell **cancers** of the lung [Rigas, 19961. Once
useful antibodies are characterized, these antibodies are used to survey **tumor** tissue samples
for P450RAI expression,
30 Protocol For Production of Mouse Hybridomas
Fusion. Feeder cells (spleen and peritoneal exudate cells) are plated.
24. . .

. . .
regard they may be included in compositions for
therapy in animals, including humans, for prernalignant epithelial cell lesions, as a prophylaxis
against **tumor** promotion in epithelial cells and treatment for dermatoses such as ichthyoses,
5 follicular disorders, benign epithelial disorders, and other proliferative skin. . .

As anti-**tumor** agents or as part of an anti-turnor formulation,

for example,
compounds of the present invention can be used in a similar. . . of the varying potency of the active ingredient, the chosen route of administration, the size of the recipient, the type of **tumor**, and the nature of the patient's
condition. The dosage to be administered is not subject to definite bounds, but it will. . . the metabolic release of the active drug to achieve its desired pharmacological and physiological effects. An oncologist skilled in the art of
cancer treatment will be able to ascertain without undue experimentation, appropriate protocols
for the effective administration of the compounds of this present. . . .
delivery vehicle can be chosen which can be targeted to a cell of interest in the
subject (e.g. a retinoid resistant **tumor** cell). Antisense nucleic acids can also be introduced
into isolated cells, such as those of the haernatopoietic system, ex vivo using. . . .
method for killing a cell which expresses the protein, wherein the cell takes up the molecule. Preferably, the cell is a **tumor** cell. Destruction of such
cells can be accomplished by labeling the molecule with a substance having toxic or
- 42 -
therapeutic activity.. . .

The invention also provides a diagnostic kit for identifying **tumor** cells
comprising a molecule which binds to a protein comprising an amino acid sequence shown in
1 0 SEQ ID NOA, for example, for incubation with a sample of **tumor** cells; means for detecting the
molecule bound to the protein, unreacted protein or unbound molecule; means for determining
the amount of protein. . .

The invention further provides a diagnostic kit for identifying **tumor** cells
comprising a nucleotide probe complementary to the sequence, or an oligonucleotide fragment
thereof, shown in SEQ ID NO:3, for example, for hybridization with mRNA from a sample of
tumor cells; means for detecting the nucleotide probe bound to mRNA in the sample with a
standard. The diagnostic kit can also. . . .
G. (1 993). Time course of induction of metabolism of all-trans retinoic acid and the
up-regulation of cellular retinoic acid-binding protein. **Cancer** Research 53, 472
Achkar, C.C., Derguini, F., Blumberg, B., Langston, A., Arthur, A. L., Speck, J., Evans, R. M.,
Bolado, Jr.,. . . .
121, 347
Akiyoshi-Shibata, M., Sakaki, T., Ohyama, Y., Noshiro, M., Okuda, K. and Yabusaki, Y. (1994),
Further oxidation of hydroxycalcidiol by **calcidiol** 24-hydroxylase. A study with the mature
enzyme expressed in Escherichia coli. European Journal of Biochemistry 224, 335

Bartel, D. and Szostak,. . .

Pharmacol. Rev. 36, 93
5 Cole et al. (1 985). Monoclonal Antibodies in **Cancer** Therapy. Allen R. Bliss, Inc.
. . .
Xenopus development. Biochem. J. 301,111
De Coster, R., Wouters, W. and Bruynseels, J. (I 996). P450-dependent enzymes as targets for
prostate **cancer** therapy. J. Ster. Biochem. Mol. Biol. 56, 133
Duell, E. A., Astrom, A., Griffiths, C. E., Chambon, P. and Voorhees,. . .

Hong, W. (1994). Retinoids and human **cancer**. In: The Retinoids. (M. Sporn, Roberts, A. and
Goodman, D.S., Editors) Raven Press, Inc.: New York.

- 45 -
Hozumi, N and Sandhu, J.S. (1 993), Recombinant antibody technology, its advent and
advances. **Cancer** Invest. 11, 714
Huse et a/. I (I 989). Science 246, 1275 -1281,
Jones, S. B., Ohno, C. K., Allenby, G.,. . . .
. . .
chemoprevention: clinical and basic studies. J. Cellular Biochem. Supplement 22, 1
Lotan, R. M. (1 995). Squamous differentiation and retinoids. **Cancer** Treat. Res. 74, 43-72,
25 Lotan, R. (1 996). Retinoids in **Cancer** Chernoprevention. Faseb J. 10, 1031
Maden, M. and Holder, N. (1992). Retinoic acid and development of the central nervous
system. [Review].. . . .
. . .
552
Mirski, S. and Cole, S. P. C. (I 989). Antigens associated with multidrug resistance in H69AR, a
small cell lung **cancer** cell line. **Cancer** Res. 49,
5719
-46 -
Monia , B. P., Johnston, J. F., Geiger, T., Muller, M. and Fabbro, D. (I 996).. . . antisense oligodeoxynucleofide targeted against C-raf kinase. Nature
Medicine 2, 668
Moon, R. C., Mehta, R.G. and Rao, K.V.N. (1994). Retinoids and **cancer** in experimental
5 animals. In: The Retinoids. (M. Sporn, Roberts, A. and Goodman, D.S., Editors) Raven Press,
Inc.: New York.
. . .
Young, C. W. and
Warrell, R. P., Jr. (1992). Clinical pharmacology of oral all-trans retinoic acid in patents with
acute promyelocytic leukemia. **Cancer** Research 52, 2138
1 5 Muindi, J. R., Young, C. W. and Warrell, R. J. (1994a). Clinical pharmacology of all-trans
retinoic. . . .

5 Metabolic phenotypes of retinoic acid and the risk of lung **cancer**. **Cancer** Res. 56, 2692
Roberts, A. B., Nichols, M, D., Newton, D. L. and Sporn, M. B. (1 979a). In vitro. . . .

Reduction of Expression of the multidrug resistance protein (MRP) in human **tumor** cells by
antisense phophorothioate oligonucleotides. Biochern. Pharamcol. 51, 461
Taimi, M. and Breitman, T.R. (1997). N hydroxyphenyiretinamide enhances retinoic acid-
induced differentiation. . .
. . .
J., Takahashi, N. and De Luca, L. M. (11 996). Retinoic Acid Metabolism and
Inhibition of Cell Proliferation: An Unexpected Liaison. **Cancer** Research 56, 675
Takeda et al., (11 985). Nature 314, 452.
. . .
Therapeutics
261, 773
Ward et aL, (11 989). Nature 341. 544
40 Warrell, R. J. (11 994). Applications for retinoids in **cancer** therapy. Seminars in Hernatol. 31, 1 -
13,
- 48 -
Warrell, R. J., Maslak, P., Eardley, A., Heller, G., Miller, W. J.. .
.

CLMEN. . . 38 The method of claim 35 wherein the organism is being treated for a disease selected from
the group consisting of **cancer**, actinic keratosis, oral leukoplakia, a secondary **tumor** of the
head and/or neck, a non-small cell lung carcinoma, a basal cell carcinoma, acute
- 73 -
promyelocytic leukemia, skin **cancer**, and a premalignancy associated actinic keratosis, acne,
psoriasis and/or ichthyosis.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.69	57.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.25

FILE 'CAPLUS' ENTERED AT 11:04:57 ON 02 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 May 2006 VOL 144 ISS 19
FILE LAST UPDATED: 1 May 2006 (20060501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 10:55:16 ON 02 MAY 2006)

FILE 'CAPLUS' ENTERED AT 10:55:27 ON 02 MAY 2006
S 19356-17-3/REG#

FILE 'REGISTRY' ENTERED AT 10:55:36 ON 02 MAY 2006
L1 1 S 19356-17-3/RN

FILE 'CAPLUS' ENTERED AT 10:55:37 ON 02 MAY 2006
L2 3122 S L1
L3 705552 S CANCER? OR TUMOR? OR NEOPLAS?
L4 59 S L2 (L) L3
L5 21 S L4 NOT PY>1998
L6 6877201 S INHIBIT? OR TREAT? OR PREVENT? OR REDUC?
L7 13 S (INHIBIT? OR TREAT? OR PREVENT? OR REDUC?) AND L5

FILE 'PCTFULL' ENTERED AT 11:02:30 ON 02 MAY 2006
L8 17 S CALCIDIOL OR CALCIFEDIOL OF CALDEROL
L9 96951 S CANCER? OR TUMOR? OR NEOPLAS?
L10 17 S L8 AND L9
L11 5 S L10 NOT PY>1998

FILE 'CAPLUS' ENTERED AT 11:04:57 ON 02 MAY 2006

=> metaboli? (L) l1
METABOLI? IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s metaboli? (L) l1
881107 METABOLI?
447949 METAB
865 METABS
448363 METAB
(METAB OR METABS)
1052618 METABOLI?
(METABOLI? OR METAB)
3122 L1
L12 873 METABOLI? (L) L1

=> and l3
AND IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l12 and l3
L13 34 L12 AND L3

=> d kwic

L13 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of inhibitors of 24-hydroxylase in the treatment of **cancer**
AB The present invention relates to a method of treating **cancer** in
a subject. The method comprises administering to a subject suffering from

cancer a therapeutically effective amount of a 24-hydroxylase inhibitor, preferably N-[4-(4-chlorophenyl)benzoyl]-2-(1H-imidazol-1-yl) 2(R)-phenyl-1-aminoethane (VID 400). In certain embodiments, the 24-hydroxylase inhibitor can. . .

ST **cancer** treatment vitamin D3 24 hydroxylase inhibitor calcitriol

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (N-CoR (nuclear receptor corepressor); use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Retinoic acid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAR-α; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Retinoic acid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAR-γ; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RXRα; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RXRβ; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRC-2 (steroid receptor coactivator-2); use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRC-3 (steroid receptor coactivator-3); use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Leukemia
(acute myeloid; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Intestine, **neoplasm**
(colorectal; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Carcinoma
(hepatocellular; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Liver, **neoplasm**
(hepatoma; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Lung, **neoplasm**
(non-small-cell carcinoma; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Drug delivery systems
(oral; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Carcinoma
(pulmonary non-small-cell; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Antitumor agents
Combination chemotherapy
Drug interactions
Esophagus, **neoplasm**
Human
Mammary gland, **neoplasm**

Multiple myeloma
Myelodysplastic syndromes
Neoplasm
Neuroglia, **neoplasm**
Ovary, **neoplasm**
Prostate gland, **neoplasm**
Stomach, **neoplasm**
(use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT Vitamin D receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT 302-79-4, Retinoic acid 5300-03-8 134404-52-7, EB 1089
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**cancer** inhibition by 24-hydroxylase inhibitor and; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT **19356-17-3**, 25-Hydroxyvitamin D3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**metab.**; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT 880898-06-6 880898-07-7 880898-08-8 880898-09-9 880898-10-2
880898-11-3 880898-12-4 880898-13-5 880898-14-6 880898-15-7
880898-16-8 880898-17-9 880898-18-0 880898-19-1 880898-20-4
880898-21-5 880898-22-6 880898-23-7
RL: PRP (Properties)
(unclaimed nucleotide sequence; use of inhibitors of 24-hydroxylase in the treatment of **cancer**)

IT 9081-36-1 65589-62-0, Vitamin D3 25-hydroxylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT 32222-06-3, Calcitriol 174262-10-3, VID 400
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

IT 53112-53-1, Vitamin D3-24 hydroxylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vitamin D3 24-hydroxylase; use of inhibitors of 24-hydroxylase in treatment of **cancer** and combination with calcitriol)

=> file his
'HIS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAPLUS'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> d his

(FILE 'HOME' ENTERED AT 10:55:16 ON 02 MAY 2006)

FILE 'CAPLUS' ENTERED AT 10:55:27 ON 02 MAY 2006
S 19356-17-3/REG#

FILE 'REGISTRY' ENTERED AT 10:55:36 ON 02 MAY 2006
L1 1 S 19356-17-3/RN

```
     FILE 'CAPLUS' ENTERED AT 10:55:37 ON 02 MAY 2006
L2          3122 S L1
L3        705552 S CANCER? OR TUMOR? OR NEOPLAS?
L4            59 S L2 (L) L3
L5            21 S L4 NOT PY>1998
L6       6877201 S INHIBIT? OR TREAT? OR PREVENT? OR REDUC?
L7            13 S (INHIBIT? OR TREAT? OR PREVENT? OR REDUC?) AND L5

     FILE 'PCTFULL' ENTERED AT 11:02:30 ON 02 MAY 2006
L8            17 S CALCIDIOL OR CALCIFEDIOL OF CALDEROL
L9         96951 S CANCER? OR TUMOR? OR NEOPLAS?
L10           17 S L8 AND L9
L11            5 S L10 NOT PY>1998

     FILE 'CAPLUS' ENTERED AT 11:04:57 ON 02 MAY 2006
L12          873 S METABOLI? (L) L1
L13           34 S L12 AND L3

=> s administ? (L) l2
        630344 ADMINIST?
L14        171 ADMINIST? (L) L2

=> s l14 and l3
L15           2 L14 AND L3

=> d ibib 1-2

L15  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:1015853  CAPLUS
DOCUMENT NUMBER:          142:1359
TITLE:                    Identification and synthesis of androgen receptor
                          modulators and therapeutic uses thereof
INVENTOR(S):              Meissner, Robert S.; Perkins, James J.
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 165 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004100874         A2    20041125    WO 2004-US13787          20040503
     WO 2004100874         A3    20060126
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004238238         A1    20041125    AU 2004-238238           20040503
     CA 2524409            AA    20041125    CA 2004-2524409          20040503
     EP 1622567            A2    20060208    EP 2004-751257           20040503
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
PRIORITY APPLN. INFO.:                       US 2003-468579P     P  20030507
                                             WO 2004-US13787     W  20040503
```

OTHER SOURCE(S): MARPAT 142:1359

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:213807 CAPLUS
DOCUMENT NUMBER: 92:213807
TITLE: The concentration of plasma vitamins A, E and D in the patients with malnutrition and patients with obstructive jaundice
AUTHOR(S): Maruyama, A.; Matsubara, Y.; Takahashi, H.; Tsutsui, M.; Fukuda, M.; Iwafuchi, M.; Muto, T.
CORPORATE SOURCE: Sch. Med., Niigata Univ., Japan
SOURCE: Jutsugo Taisha Kenkyu Kaishi (1980), 14(1), 267-71
CODEN: JTKKDB; ISSN: 0389-5556
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

=> d kwic 1

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . skin, male hypogonadism, post-menopausal symptoms in women, female sexual dysfunction, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic **cancer**, renal **cancer**, arthritis and joint repair, alone or in combination with other active agents. In addition, these compds. are useful as pharmaceutical. . .
IT Cachexia
(**cancerous**; identification and synthesis of androgen receptor modulators and therapeutic uses thereof)
IT Arthritis
Atherosclerosis
Autoimmune disease
Hematopoietic disorders
Human
Hypercholesterolemia
Kidney, **neoplasm**
Muscular dystrophy
Osteoporosis
Pancreas, **neoplasm**
Periodontium, disease
(identification and synthesis of androgen receptor modulators and therapeutic uses thereof)
IT 50-28-2, Estradiol, biological studies 53-16-7, Estrone, biological studies 67-96-9, Dihydrotachysterol 67-98-1, Mer-25 68-22-4, Norethindrone 71-58-9, Medroxyprogesterone acetate 471-34-1, Calcium carbonate, biological studies 911-45-5, Clomiphene 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, derivs. 1845-11-0, Nafoxidine 2809-21-4 4717-38-8, 17β-Ethynyl estradiol 5863-35-4, CI-628 7440-70-2D, Calcium, salts 7681-49-4, Sodium fluoride, biological studies 7693-13-2, Calcium citrate 9002-64-6, Parathyroid hormone 9007-12-9, Calcitonin 10540-29-1, Tamoxifen 10596-23-3 12001-79-5, Vitamin K 12001-79-5D, Vitamin K, derivs. 15690-55-8, Zuclomiphene 15690-57-0, Enclomiphene 16984-48-8D, Fluoride, salts **19356-17-3**, 25-Hydroxy-vitamin D3 20859-36-3, Monosodium fluorophosphate 32222-06-3, 1α,25-Dihydroxy vitamin D3 35212-22-7, Ipriflavone 40391-99-9, 3-Amino-1-hydroxypropylidene-1,1-bisphosphonic acid 41294-56-8 47931-85-1, Salmon calcitonin 50948-44-2, U-11, biological studies 52232-67-4, 1-34-Parathormone (human) 54573-75-0 56287-31-1, CI-680 57333-95-6 57333-96-7 61912-98-9, Insulin-like growth factor 63132-39-8 66376-36-1, 4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid 67763-96-6, IGF I 67763-97-7, IGF II 68893-82-3, 1-84-Parathormone (human) 75330-75-5, Lovastatin 78994-23-7, Levormeloxifene 79778-41-9 79902-63-9, Simvastatin 81093-37-0,

Pravastatin 82413-20-5, Droloxifene 83805-11-2 84449-90-1, Raloxifene 89778-26-7, Toremifene 93957-54-1, Fluvastatin 103909-75-7, 22-Oxacalcitriol 104121-92-8, ED71 104361-73-1 105462-24-6 106096-92-8, AFGF 106096-93-9, Basic fibroblast growth factor 112965-21-6, Calcipotriol 116057-75-1, Idoxifene 116162-22-2 118072-93-8 118694-43-2, Ro 23-7553 121009-77-6 129318-43-0, 4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt 130447-37-9, 19-Nor-1α,25-dihydroxy vitamin D3 131875-08-6, KH1060 134399-24-9 134404-52-7, EB1089 134523-00-5, Atorvastatin 134523-84-5 141750-63-2, Nisvastatin 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 180064-38-4 180916-16-9, Lasofoxifene 182133-25-1, Arzoxifene 182167-02-8, EM-652 182167-03-9, EM-800 193830-08-9, GDF5 198481-33-3, TSE 424 287714-41-4, Rosuvastatin 304853-26-7, Growth hormone, secretagogue 530109-46-7, 1-Hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid 583063-07-4, 1-84-Parathormone (human) 797050-64-7, 555A 797050-81-8, U 100A
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(further **administered** with androgen modulator treatment; identification and synthesis of androgen receptor modulators and therapeutic uses thereof)

```
=> d his

     (FILE 'HOME' ENTERED AT 10:55:16 ON 02 MAY 2006)

     FILE 'CAPLUS' ENTERED AT 10:55:27 ON 02 MAY 2006
               S 19356-17-3/REG#

     FILE 'REGISTRY' ENTERED AT 10:55:36 ON 02 MAY 2006
L1             1 S 19356-17-3/RN

     FILE 'CAPLUS' ENTERED AT 10:55:37 ON 02 MAY 2006
L2          3122 S L1
L3        705552 S CANCER? OR TUMOR? OR NEOPLAS?
L4            59 S L2 (L) L3
L5            21 S L4 NOT PY>1998
L6       6877201 S INHIBIT? OR TREAT? OR PREVENT? OR REDUC?
L7            13 S (INHIBIT? OR TREAT? OR PREVENT? OR REDUC?) AND L5

     FILE 'PCTFULL' ENTERED AT 11:02:30 ON 02 MAY 2006
L8            17 S CALCIDIOL OR CALCIFEDIOL OF CALDEROL
L9         96951 S CANCER? OR TUMOR? OR NEOPLAS?
L10           17 S L8 AND L9
L11            5 S L10 NOT PY>1998

     FILE 'CAPLUS' ENTERED AT 11:04:57 ON 02 MAY 2006
L12          873 S METABOLI? (L) L1
L13           34 S L12 AND L3
L14          171 S ADMINIST? (L) L2
L15            2 S L14 AND L3

=> s treat? (L) l2
       3348121 TREAT?
L16        285 TREAT? (L) L2

=> s l16 and l3
L17          22 L16 AND L3

=> s l17 not py>1998
       7447350 PY>1998
```

L18 6 L17 NOT PY>1998

=> d ibib 1-6

L18 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:452435 CAPLUS
DOCUMENT NUMBER: 129:131487
TITLE: Markers of bone turnover in patients with differentiated thyroid **cancer** with and following withdrawal of thyroxine suppressive therapy
AUTHOR(S): Toivonen, Jukka; Tahtela, Riitta; Laitinen, Kalevi; Risteli, Juha; Valimaki, Matti J.
CORPORATE SOURCE: Department of Medicine, Helsinki University Central Hospital, Helsinki, FIN-00290, Finland
SOURCE: European Journal of Endocrinology (1998), 138(6), 667-673
CODEN: EJOEEP; ISSN: 0804-4643
PUBLISHER: BioScientifica
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:201142 CAPLUS
DOCUMENT NUMBER: 104:201142
TITLE: Inhibitory effect of 1α,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line
AUTHOR(S): Nagakura, Kazuhiko; Abe, Etsuko; Suda, Tatsuo; Hayakawa, Masamichi; Nakamura, Hiroshi; Tazaki, Hiroshi
CORPORATE SOURCE: Dep. Urol., Natl. Def. Med. Coll., Saitama, 359, Japan
SOURCE: Kidney International (1986), 29(4), 834-40
CODEN: KDYIA5; ISSN: 0085-2538
DOCUMENT TYPE: Journal
LANGUAGE: English

L18 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:62812 CAPLUS
DOCUMENT NUMBER: 104:62812
TITLE: Demonstration and characterization of a 1α,25-(dihydroxyvitamin) D3 receptor-like macromolecule in cultured rat pituitary cells
AUTHOR(S): Haug, Egil; Gautvik, Kaare M.
CORPORATE SOURCE: Horm. Lab., Aker Hosp., Oslo, Norway
SOURCE: Journal of Steroid Biochemistry (1985), 23(5A), 625-35
CODEN: JSTBBK; ISSN: 0022-4731
DOCUMENT TYPE: Journal
LANGUAGE: English

L18 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:613909 CAPLUS
DOCUMENT NUMBER: 103:213909
TITLE: Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells
AUTHOR(S): Costa, Elizabeth M.; Hirst, Margaret A.; Feldman, David
CORPORATE SOURCE: Sch. Med., Stanford Univ., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1985), 117(5), 2203-10
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English

L18 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:417469 CAPLUS
DOCUMENT NUMBER: 103:17469
TITLE: 1α,25-Dihydroxyvitamin D3 specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line
AUTHOR(S): Franceschi, Renny T.; James, Wilbur M.; Zerlauth, Gerold
CORPORATE SOURCE: Dep. Nutr., Harvard Sch. Public Health, Boston, MA, 02115, USA
SOURCE: Journal of Cellular Physiology (1985), 123(3), 401-9
CODEN: JCLLAX; ISSN: 0021-9541
DOCUMENT TYPE: Journal
LANGUAGE: English

L18 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:80440 CAPLUS
DOCUMENT NUMBER: 100:80440
TITLE: Induction of a high phagocytic capability in P388D1, a macrophage-like **tumor** cell line, by 1α,25-dihydroxyvitamin D3
AUTHOR(S): Goldman, Rachel
CORPORATE SOURCE: Dep. Membr. Res., Weizmann Inst. Sci., Rehovot, Israel
SOURCE: Cancer Research (1984), 44(1), 11-19
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d abs 2

L18 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AB Vitamin D3 derivs. suppressed the growth of a human renal carcinoma cell line (KU-2) in a monolayer culture and also clonogenicity in a soft agar culture dose-dependently. Of the vitamin D3 derivs. tested, 1α,25-dihydroxyvitamin D3 [32222-06-3] was the most potent in inhibiting cell growth, followed successively by 1α,24R,25-trihydroxyvitamin D3 [56142-94-0], 25-hydroxyvitamin D3 [**19356-17-3**], 1α-hydroxyvitamin D3 [41294-56-8] and 24R,25-dihydroxyvitamin D3 [55721-11-4] in that order. Anal. of the cell cycle phase of **treated** and nontreated KU-2 cells, revealed that the action of 1α,25-dihydroxyvitamin D3 was not phase specific but simply extended the doubling time of the cells. Radioreceptor assay and sucrose d. gradient anal. of the cytosol showed that KU-2 cells contained a 3.2 S receptor protein to which 1α,25-dihydroxyvitamin D3 was specifically bound (dissociation constant 20.8 pM, binding capacity 87 fmole/mg protein or 4000 mols./cell). On the other hand, the equilibrium dissociation constant of internalization of 1α,25-dihydroxyvitamin D3 (Kint) by intact KU-2 cells was 1.2 nM and the internalizing capacity was 33 fmole/8 + 106 cells (2500 mols./cell) in the 10% serum medium, which was the same as that used in the growth study. This Kint value was very close to the half-maximal dose in growth inhibition. Also the affinity of various vitamin D3 derivs. for binding to the cytosol receptor in the KU-2 cells was closely related to the ability to inhibit growth of the cells. Thus, the actions of vitamin D3 derivs. in inhibiting proliferation and clonogenicity of KU-2 cells are affected by a receptor-mediated mechanism, and the active form of vitamin D3 may be one of the regulatory factors affecting the proliferation and other biol. functions of renal carcinoma cells.

=> d ibib abs 1-6

L18 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:452435 CAPLUS
DOCUMENT NUMBER: 129:131487
TITLE: Markers of bone turnover in patients with differentiated thyroid **cancer** with and following withdrawal of thyroxine suppressive therapy
AUTHOR(S): Toivonen, Jukka; Tahtela, Riitta; Laitinen, Kalevi; Risteli, Juha; Valimaki, Matti J.
CORPORATE SOURCE: Department of Medicine, Helsinki University Central Hospital, Helsinki, FIN-00290, Finland
SOURCE: European Journal of Endocrinology (1998), 138(6), 667-673
CODEN: EJOEEP; ISSN: 0804-4643
PUBLISHER: BioScientifica
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To study whether levothyroxine (LT4) suppressive therapy exposes patients with differentiated thyroid **cancer** (TC) to an increased risk of osteoporosis. Markers of bone formation (serum alkaline phosphatase (ALP), osteocalcin (OC), type I procollagen carboxyterminal (PICP) and aminoterminal (PINP) propeptide) and resorption (serum type I collagen carboxyterminal telopeptide (ICTP) and urine hydroxyproline (HOP)), as well as serum intact parathyroid hormone (PTH), 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D (1,25(OH)2-D) were measured in 29 patients (25 women, 4 men) with a median age of 45 yr, and in 38 age- and sex-matched controls. In a subgroup of 14 patients the measurements were repeated after 5 wk' interruption of LT4 therapy. Since the primary treatment of TC the patients had used TSH suppressive doses of LT4 (a mean daily dose of 215 μg) for 9 to 11 yr. The bone mineral d. (BMD) of patients and controls was measured by dual energy x-ray absorptiometry. When on T4 therapy, patients had significantly higher mean levels of ALP (+21%, P<0.05), OC (+35%, P<0.01), PICP (+10%, P<0.05), PINP (+46%, P<0.001), ICTP (+21%, P<0.05), and HOP (+37%, P<0.001) compared with controls. After stopping treatment, OC (-42%, P<0.001), PINP (-7%, P<0.05), and ICTP (-54%,P<0.0001) decreased, whereas PICP (+24%, P<0.001) and 1,25-(OH)2D (+29%, P<0.01) increased. BMD of the lumbar spine and the upper femur was similar in patients and controls. Patients with differentiated TC have high bone turnover when on LT4 suppressive therapy. After withdrawing treatment both bone formation and resorption decrease acutely. During development of hypothyroidism, serum PICP and PINP, which form from the same type I procollagen mol. and should change similarly, behaved differently. This may be due to different effects of hypothyroidism on their removal through sep. receptors in the liver.
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:201142 CAPLUS
DOCUMENT NUMBER: 104:201142
TITLE: Inhibitory effect of 1α,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line
AUTHOR(S): Nagakura, Kazuhiko; Abe, Etsuko; Suda, Tatsuo; Hayakawa, Masamichi; Nakamura, Hiroshi; Tazaki, Hiroshi
CORPORATE SOURCE: Dep. Urol., Natl. Def. Med. Coll., Saitama, 359, Japan
SOURCE: Kidney International (1986), 29(4), 834-40
CODEN: KDYIA5; ISSN: 0085-2538
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Vitamin D3 derivs. suppressed the growth of a human renal carcinoma cell line (KU-2) in a monolayer culture and also clonogenicity in a soft agar culture dose-dependently. Of the vitamin D3 derivs. tested, 1α,25-dihydroxyvitamin D3 [32222-06-3] was the most potent in

inhibiting cell growth, followed successively by 1α,24R,25-trihydroxyvitamin D3 [56142-94-0], 25-hydroxyvitamin D3 [**19356-17-3**], 1α-hydroxyvitamin D3 [41294-56-8] and 24R,25-dihydroxyvitamin D3 [55721-11-4] in that order. Anal. of the cell cycle phase of **treated** and nontreated KU-2 cells, revealed that the action of 1α,25-dihydroxyvitamin D3 was not phase specific but simply extended the doubling time of the cells. Radioreceptor assay and sucrose d. gradient anal. of the cytosol showed that KU-2 cells contained a 3.2 S receptor protein to which 1α,25-dihydroxyvitamin D3 was specifically bound (dissociation constant 20.8 pM, binding capacity 87 fmole/mg protein or 4000 mols./cell). On the other hand, the equilibrium dissociation constant of internalization of 1α,25-dihydroxyvitamin D3 (Kint) by intact KU-2 cells was 1.2 nM and the internalizing capacity was 33 fmole/8 + 106 cells (2500 mols./cell) in the 10% serum medium, which was the same as that used in the growth study. This Kint value was very close to the half-maximal dose in growth inhibition. Also the affinity of various vitamin D3 derivs. for binding to the cytosol receptor in the KU-2 cells was closely related to the ability to inhibit growth of the cells. Thus, the actions of vitamin D3 derivs. in inhibiting proliferation and clonogenicity of KU-2 cells are affected by a receptor-mediated mechanism, and the active form of vitamin D3 may be one of the regulatory factors affecting the proliferation and other biol. functions of renal carcinoma cells.

L18 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:62812 CAPLUS
DOCUMENT NUMBER: 104:62812
TITLE: Demonstration and characterization of a 1α,25-(dihydroxyvitamin) D3 receptor-like macromolecule in cultured rat pituitary cells
AUTHOR(S): Haug, Egil; Gautvik, Kaare M.
CORPORATE SOURCE: Horm. Lab., Aker Hosp., Oslo, Norway
SOURCE: Journal of Steroid Biochemistry (1985), 23(5A), 625-35
CODEN: JSTBBK; ISSN: 0022-4731
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The presence of specific receptors for 1α,25-dihydroxycholecalciferol (I) [32222-06-3] were demonstrated in the rat pituitary **tumor** GH3 cells. GH3 cell cytosol was incubated with [3H]I at 0-4°. Maximal binding was obtained between 2 and 6 h, and Scatchard anal. showed 1 single class of binding sites with dissociation constant of 0.33 nM and a maximum binding capacity of 103 fmol/mg cytosol protein. Competitive binding expts. revealed the following potency order: I > 25-hydroxyvitamin D3 [**19356-17-3**] > 1α-hydroxyvitamin D3 [41294-56-8], 24,25-dihydroxyvitamin D3 [40013-87-4]. In contrast, corticosterone, testosterone, progesterone, and estradiol showed negligible ability to displace [3H]I from its receptor. Sucrose gradient ultracentrifugation in high salt concentration revealed that GH3 cell cytosol possessed at 3.7 S I receptor protein which was inactivated by heating and protease **treatment**, but not after incubation with DNase or RNase. The receptor protein aggregated in salt-free sucrose gradients since the 3.7 S complex was shifted reversibly to a .apprx.6 S form. Isoelec. focussing localized most of the [3H]I to a protein peak with an isoelec. point of .apprx.6 (+I 5.8-6.2). Since this I receptor protein has similar properties to the corresponding receptors found in normal rat tissues, lactotrophs and somatotrophs may represent true target cells for I.

L18 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:613909 CAPLUS
DOCUMENT NUMBER: 103:213909
TITLE: Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells

AUTHOR(S): Costa, Elizabeth M.; Hirst, Margaret A.; Feldman, David
CORPORATE SOURCE: Sch. Med., Stanford Univ., Stanford, CA, 94305, USA
SOURCE: Endocrinology (1985), 117(5), 2203-10
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The pig kidney cell line (LLC-PK1) has been shown to possess 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] [32222-06-3] receptors and to exhibit functional responses to vitamin D metabolites. These receptors appear to undergo homologous up-regulation by 1,25-(OH)2D3 and other vitamin D analogs. This phenomenon was also observed in other cell lines, including human skin fibroblasts and human mammary **cancer** cells (MCF-7). **Treatment** with active hormone or vitamin D analogs results in a substantial increase (200-400%) in the number of 1,25-(OH)2D3 receptors without altering the affinity of receptor for hormone. The up-regulated receptor, like the basal receptor, has an apparent Kd of .apprx.0.04 nM and sediments at 3.3S on hypertonic sucrose gradients. In addition, .apprx.50% of the total receptors from both control and **treated** cells bind to DNA-cellulose and elute at 0.18M KCl. These results indicate that the up-regulated receptor is similar to the classical 1,25-(OH)2D3 receptor. While the time necessary to achieve the maximal receptor increment is 16-20 h, there is a rapid component in the rise observed within 5 min. The maximal effect persists for 4-6 h after hormone removal. The increased binding is not a result of differential receptor localization or extractability. 1,25-(OH)2D3, 1,24,25-trihydroxyvitamin D3 [50648-94-7], 24,25-(OH)2D3 [40013-87-4], and 25-hydroxyvitamin D3 [**19356-17-3**] all increase receptor binding to similar levels, and the dose required closely reflects the affinities of the various metabolites for the receptor. **Treatment** of cells with the RNA synthesis inhibitor actinomycin D indicates that the increase in receptors is partially dependent on RNA synthesis. Mutant skin fibroblasts from patients with vitamin D-dependent rickets type II, containing nonresponsive 1,25-(OH)2D3 receptors, failed to exhibit the characteristic up-regulation observed in normal cells. Taken together, these results indicate that vitamin D metabolites regulate the number of 1,25-(OH)2D3 receptors in part by receptor occupancy and, more importantly, by a receptor-mediated induction mechanism.

L18 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:417469 CAPLUS
DOCUMENT NUMBER: 103:17469
TITLE: 1α,25-Dihydroxyvitamin D3 specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line
AUTHOR(S): Franceschi, Renny T.; James, Wilbur M.; Zerlauth, Gerold
CORPORATE SOURCE: Dep. Nutr., Harvard Sch. Public Health, Boston, MA, 02115, USA
SOURCE: Journal of Cellular Physiology (1985), 123(3), 401-9
CODEN: JCLLAX; ISSN: 0021-9541
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The ability of the hormonally active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 [32222-06-3], to affect cell growth, morphol., and fibronectin production was examined using the MG-63 human osteosarcoma cell line. Hormone **treatment** reduced cell growth rate, saturation d. and [3H]thymidine incorporation. Inhibition was specific for 1α,25-dihydroxyvitamin D3 relative to other vitamin D metabolites (1α,25-dihydroxyvitamin D3 > 25-hydroxyvitaminD3 [**19356-17-3**] > 24R,25-dihydroxyvitamin D3 [55721-11-4] > vitamin D3 [67-97-0]), was antagonized by high concns. of serum, and was readily reversed by removal of 1α,25-dihydroxyvitamin D3 from the culture

medium. Hormone **treatment** also increased cell-associated alkaline phosphatase [9001-78-9] activity up to 2-fold and altered morphol. such that **treated** cells were more spread out on the culture dish and contained more cytoplasmic processes. 1α,25-Dihydroxyvitamin D3 increased cellular and medium concns. of fibronectin, a glycoprotein known to be involved in cellular adhesiveness. MG-63 cells contained a specific 1α,25-dihydroxyvitamin D3 receptor which may mediate these responses.

L18 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:80440 CAPLUS
DOCUMENT NUMBER: 100:80440
TITLE: Induction of a high phagocytic capability in P388D1, a macrophage-like **tumor** cell line, by 1α,25-dihydroxyvitamin D3
AUTHOR(S): Goldman, Rachel
CORPORATE SOURCE: Dep. Membr. Res., Weizmann Inst. Sci., Rehovot, Israel
SOURCE: Cancer Research (1984), 44(1), 11-19
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 1α,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] [32222-06-3] induced a high phagocytic capability in the macrophage-like murine **tumor** cell line P388D1. Induction of phagocytic capability by 1,25-(OH)2D3 was dose-dependent in the range 0.2-5.0 ng/mL, required the continuous presence of the secosteroid in culture, and was reversible. 25-Hydroxyvitamin D3 [**19356-17-3**] was an effective inducer only at .apprx.500 ng/mL, whereas 24R,25-dihydroxyvitamin D3 [55721-11-4] was ineffective. The induction of the high phagocytic capability was neither accompanied by increased synthesis of lysozyme [9001-63-2] nor closely associated with an inhibitory effect on cellular proliferation. P388D1 cells bound (without ingestion) nonopsonized sheep erythrocytes (sheep RBC), and the binding increased in 1,25-(OH)2D3-**treated** cells. Fc receptor-mediated binding of IgG-coated sheep RBC was not modulated in 1,25-(OH)2D3-**treated** cells, but the cells acquired an Fc receptor-mediated phagocytic capability that was expressed only when preformed P388D1-sheep RBC rosettes were further exposed to IgG. Several differentiation agents of myeloid leukemia cells (including dexamethasone [50-02-2]) were not effective in inducing the high-phagocytic phenotype, whereas retinoic acid [302-79-4] was very effective. Different myeloid or macrophage-like **tumors** (WEHI-265, J774.2, PU-5, and WEHl-3) were variable in their response to 1,25-(OH)2D3.

```
=> s calcidiol or calcifediol of calderol
          176 CALCIDIOL
           42 CALCIFEDIOL
            0 CALDEROL
            0 CALCIFEDIOL OF CALDEROL
                (CALCIFEDIOL(1W)CALDEROL)
L19       176 CALCIDIOL OR CALCIFEDIOL OF CALDEROL

=> s treat (L) l19
        64042 TREAT
         7797 TREATS
        71461 TREAT
                (TREAT OR TREATS)
L20         0 TREAT (L) L19

=> s treat? (L) l19
      3348121 TREAT?
L21        35 TREAT? (L) L19
```

```
=> s l21 not py>1998
       7447350 PY>1998
L22          21 L21 NOT PY>1998

=> s l22 and l3
L23           0 L22 AND L3

=> s l21 and l3
L24           3 L21 AND L3

=> d ibib 1-3

L24  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:690565  CAPLUS
DOCUMENT NUMBER:          143:452097
TITLE:                    Vitamin D3 Metabolism in Human Glioblastoma
                          Multiforme: Functionality of CYP27B1 Splice Variants,
                          Metabolism of Calcidiol, and Effect of Calcitriol
AUTHOR(S):                Diesel, Britta; Radermacher, Jens; Bureik, Matthias;
                          Bernhardt, Rita; Seifert, Markus; Reichrath, Joerg;
                          Fischer, Ulrike; Meese, Eckart
CORPORATE SOURCE:         Institut fuer Humangenetik, Germany
SOURCE:                   Clinical Cancer Research (2005), 11(15), 5370-5380
                          CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER:                American Association for Cancer Research
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
REFERENCE COUNT:          49    THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:995984  CAPLUS
DOCUMENT NUMBER:          141:389290
TITLE:                    New calcitriol analogs and therapeutic use in treating
                          mast cell associated diseases
INVENTOR(S):              Moussy, Alain; Kinet, Jean-Pierre
PATENT ASSIGNEE(S):       AB Science, Fr.
SOURCE:                   PCT Int. Appl., 70 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004098612         A2    20041118    WO 2004-IB1871           20040507
     WO 2004098612         A3    20050210
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRIORITY APPLN. INFO.:                       US 2003-468295P     P  20030507
                                             US 2003-480224P     P  20030623
OTHER SOURCE(S):          MARPAT 141:389290
```

L24 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:215843 CAPLUS
DOCUMENT NUMBER: 140:386408
TITLE: Studies on the influence of vitamin D3 metabolites on apoptosis induction in human **neoplastic** cells
AUTHOR(S): Gruber, Beata M.; Anuszewska, Elzbieta L.
CORPORATE SOURCE: Department of Biochemistry and Biopharmaceuticals, National Institute of Public Health, Warsaw, 00-725, Pol.
SOURCE: Acta Poloniae Pharmaceutica (2003), 60(5), 363-366
CODEN: APPHAX; ISSN: 0001-6837
PUBLISHER: Polish Pharmaceutical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3121 REFERENCES IN FILE CA (1907 TO DATE)
44 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3122 REFERENCES IN FILE CAPLUS (1907 TO DATE)